Datasets:

hackint0sh
/

New-Dataset

Dataset card Data Studio Files Files and versions Community

Split (1)

train · 22k rows

Record stringlengths 1 197k
<\|newrecord\|> nctId: NCT06280170 id: ST11480 briefTitle: AI to Support Mental Health Case Management Providers overallStatus: ENROLLING_BY_INVITATION date: 2024-02-19 date: 2025-06-30 date: 2025-12-31 date: 2024-02-28 date: 2024-02-28 name: Eleos Health class: INDUSTRY name: Centerstone Research Institute briefSummary: The goal of this clinical trial is to assess the effectiveness of an artificial intelligence (AI) platform for case managers in a nonprofit health system specializing in mental health and substance use disorder. The main questions it aims to answer are:
1. Is the AI platform acceptable and feasible for case managers?
2. Does the AI platform improve providers' productivity and reported interventions? Participants will be approximately 30 case managers and their 250 adult clients receiving case management services. Researchers will compare the provider productivity and work satisfaction prior to the implementation of the AI platform to following its implementation. conditions: Depressive Disorder conditions: Anxiety Disorders conditions: Substance Use Disorders conditions: Post Traumatic Stress Disorder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: SEQUENTIAL interventionModelDescription: This study will follow a stepped-wedge, randomized controlled design, where each provider team will undergo two phases: SAU and the AI platform phase. All teams will initially start with SAU, and the AI platform will be sequentially introduced to teams over time. Teams will be randomly assigned to different time periods for the AI platform phase using simple randomization. The order of implementation will be determined by randomly selecting the number of the team from sealed envelopes every two months. In both phases, the study will enroll new and existing clients. At the end of the trial all teams would have used Eleos for a few months primaryPurpose: OTHER masking: NONE maskingDescription: The masking in this study involves a differential approach between providers and clients. Providers will be aware of whether they are in the Services-As-Usual (SAU) or Artificial Intelligence (AI) phase. However, participating clients will not be informed about the platform their provider is using to document their therapy sessions. count: 280 type: ESTIMATED name: Artificial Intelligence platform for case managers measure: Case manager satisfaction measure: Case manager productivity measure: Case manager note completion time measure: Clients' crisis services utilization sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Centerstone city: Alton state: Illinois zip: 62002 country: United States lat: 38.8906 lon: -90.18428 hasResults: False
<\|newrecord\|> nctId: NCT06280157 id: MVX0007 id: 332126 type: OTHER domain: IRAS briefTitle: A Follow up Study of Group B Streptococcus Vaccine (GBS-NN/NN2 Vaccine) in Healthy Volunteers overallStatus: ENROLLING_BY_INVITATION date: 2024-01-18 date: 2028-01 date: 2028-01 date: 2024-02-28 date: 2024-02-28 name: Minervax ApS class: OTHER name: Simbec-Orion Group briefSummary: The goal of this follow-up study is to investigate the persistence of the immune response induced by the GBS-NN/NN2 vaccine in women who have participated in study MVX0002, and/or in study MVX0003 with GBS-NN/NN2 vaccine and received 1, 2 or 3 doses of GBS-NN/NN2. The main question it aims to answer is to determine the persistence of the immune response induced by the GBS-NN/NN2 vaccine by measuring antibody concentrations.
Participants who had received a primary course of GBS-NN/NN2 in Study MVX0002 and/or MVX0003 will be invited to return to have a single yearly blood sample of approximately 10 mL collected 2 to 5 years after the completion of the previous vaccination. conditions: Group B Streptococcus Infection studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 55 type: ESTIMATED name: GBS-NN/NN2 measure: Antibody Concentration Specific for GBS-NN and GBS-NN2 measure: Antibody Responses Specific to AlpCN, RibN, Alp1N and Alp2-3N sex: FEMALE minimumAge: 18 Years maximumAge: 40 Years stdAges: ADULT facility: Simbec-Orion Clinical Pharmacology city: Merthyr Tydfil state: Pentrebach Merthyr Tydfil CF48 4DR country: United Kingdom lat: 51.74794 lon: -3.37779 hasResults: False
<\|newrecord\|> nctId: NCT06280144 id: PF20230428 briefTitle: Post-marketing Study of Lyophilized Nasal Spray Live Attenuated Influenza Vaccine overallStatus: RECRUITING date: 2023-09-22 date: 2024-06-30 date: 2024-10-30 date: 2024-02-28 date: 2024-02-28 name: Changchun BCHT Biotechnology Co. class: INDUSTRY name: Hu Bei province Center for Disease control and prevention name: The Inner Mongolia Autonomous Region Center for Disease Control and Prevention briefSummary: To evaluate the protective effect 14 days after the live attenuated influenza vaccine; To evaluate the protective effect of vaccination with live attenuated influenza vaccine; To evaluate the safety of freeze-dried nasal spray live attenuated influenza vaccine; To evaluate the detoxification and genetic stability of lyophilized nasal spray vaccine.
To evaluate the protective effect of novel coronavirus after 14 days of inoculation with the live attenuated influenza vaccine. conditions: Influenza Prevention studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 6080 type: ESTIMATED name: Influenza Vaccine, Live, Nasal, Freeze-dried name: Sterile water for inhalation measure: Primary influenza protective effect endpoint measure: Primary influenza protective effect endpoint measure: Secondary protective efficacy endpoint measure: Secondary protective efficacy endpoint measure: Secondary protective efficacy endpoint measure: Safety measure: Study on detoxification measure: Protective effect of COVID-19 cases. sex: ALL minimumAge: 3 Years maximumAge: 17 Years stdAges: CHILD status: RECRUITING city: Chi Feng state: Inner Mongolia Autonomous Region zip: 024000 country: China name: Xiaoling Tian role: CONTACT phone: 13848710296 email: [email protected] hasResults: False
<\|newrecord\|> nctId: NCT06280131 id: multiple sclerosis and pulse briefTitle: The Efficacy of Pulse Therapy in Acute Relapse in Multiple Sclerosis Patients: overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2025-03-01 date: 2025-04-01 date: 2024-02-28 date: 2024-02-28 name: Assiut University class: OTHER briefSummary: This work is aimed to assess the short term effect of pulse therapy on clinical and neurophysiological course before and after pulse therapy in order to understand the possible mechanism of action of steroid therapy on RRMS patients low-dose oral treatment should also be retained for patients in whom this approach seems appropriate conditions: Multiple Sclerosis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 30 type: ESTIMATED measure: to evaluate efficacy of a pulse therapy on clinical outcome measure: clinical correlation between clinical scales scores and neurophysiological changes(visual evoked potional measure: clinical correlation between clinical scales scores and neurophysiological changes( cortical exitability parameters) sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<\|newrecord\|> nctId: NCT06280118 id: EFCPR008 briefTitle: The Effect of Fatigue on CPR overallStatus: COMPLETED date: 2023-04-20 date: 2023-06-20 date: 2023-10-25 date: 2024-02-28 date: 2024-02-28 name: Artvin Coruh University class: OTHER briefSummary: Background: This study, in contrast to the previous studies, generated a scenario of fatigue in an earthquake scenario and aimed to measure the effect of fatigue on the quality of cardiopulmonary resuscitation (CPR) performed by paramedics in a debris course.
Methods: The study was designed as a randomized controlled trial. The sample, consisting of 84 paramedic students, was randomly assigned as 42 control and 42 experimental groups. Fatigue was created in the participants by rehearsing the process of removing and transporting earthquake victims from the rubble through the prepared track. A personal information form and a CPR measurement form were used to obtain the data. The simulator was used to evaluate the accuracy of CPR. The collected data were analysed with the statistical program. conditions: Resuscitation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized controlled trial primaryPurpose: SCREENING masking: NONE count: 84 type: ACTUAL name: Fatigue measure: Correct number of ventilations measure: Correct number of compression measure: CPR duration sex: ALL minimumAge: 18 Years maximumAge: 24 Years stdAges: ADULT facility: Resuscitation simulation laboratory of Artvin Çoruh University Health Services Vocational School city: Artvin zip: 08000 country: Turkey lat: 41.18161 lon: 41.82172 hasResults: False
<\|newrecord\|> nctId: NCT06280105 id: 2023_148_01 briefTitle: A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib overallStatus: NOT_YET_RECRUITING date: 2024-03-31 date: 2026-03-31 date: 2027-03-31 date: 2024-02-28 date: 2024-02-28 name: Meng Chao Hepatobiliary Hospital of Fujian Medical University class: OTHER briefSummary: To evaluate the efficacy and safety of cadonilimab combined with Regorafenib in patients with hepatocellular carcinoma who failed camrelizumab plus apatinib. conditions: Hepatocellular Carcinoma studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 40 type: ESTIMATED name: Cadonilimab+regorafenib measure: objective response rate (ORR) per RECIST1.1 measure: Progression-free survival（PFS） measure: Overall survival（OS） measure: Duration of response (DOR) measure: Occurence of AE and SAE sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Mengchao Hepatobiliary Hospital, Fujian Medical University city: Fuzhou state: Fujian country: China lat: 26.06139 lon: 119.30611 hasResults: False
<\|newrecord\|> nctId: NCT06280092 id: 23-009133 briefTitle: Allogenic Adipose-derived Mesenchymal Stem Cells(AMSCs) for Epilepsy During Deep Brain Stimulation(DBS) Surgery overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-03 date: 2025-03 date: 2024-02-28 date: 2024-04-08 name: Sanjeet S. Grewal class: OTHER briefSummary: This study is a non-randomized, open label, phase 1 clinical trial to evaluate the fesibility and safety of intrathalamic delivery of MSCs during standard of care DBS surgery for epilepsy.
Subjects will be screened at our outpatient clinic and interested qualified subjects will be consented and offered participation in this trial. Once consent has been obtained, patients will undergo a standard preoperative evaluation which includes baseline laboratory values and a high-definition MRI. Patients will then undergo a stereotactic procedure for bilateral thalamic implantation of DBS leads through the ClearPoint® system. After the thalamic target for DBS is identified, cells will be infused directly into the anterior nucleus of the thalamus previous to lead implantation.
Patients will be followed in the outpatient setting for up to a year after therapy application.
Surgical, clinical, and radiographic data will be obtained during these visits conditions: Epilepsy studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: A single dose of 5x10\^6 AMSCs will be resuspended in 1ml of LRS and infused via intraparenchymal at the time of DBS surgery primaryPurpose: OTHER masking: NONE maskingDescription: This is an unmasked study count: 5 type: ESTIMATED name: AMSCs measure: Primary Objective measure: Secondary Objective sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<\|newrecord\|> nctId: NCT06280079 id: LIPCAL-ALS II 1.1 briefTitle: Ultra-high-caloric, Fatty Diet in ALS acronym: LIPCAL-ALS II overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2027-05-01 date: 2027-05-01 date: 2024-02-28 date: 2024-03-01 name: University of Ulm class: OTHER briefSummary: This study aims at evaluating efficacy and tolerability of an ultra-high-caloric, fatty diet (UFD) compared to placebo in patients with amyotrophic lateral sclerosis (ALS). conditions: Amyotrophic Lateral Sclerosis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 392 type: ESTIMATED name: Ultra-high-caloric fatty diet name: Placebo measure: Survival measure: Amyotrophic Lateral Sclerosis Functional Rating Scale Revised measure: Rasch Overall Amyotrophic Lateral Sclerosis Disability Scale measure: Individual Quality of Life measure: Slow vital capacity measure: Survival measure: Survival measure: Time to death measure: Time to tracheostomy measure: Time to permanent continous ventilator dependence measure: Ventilation assistance-free survival measure: Body Mass Index measure: Council of Nutrition Appetite Questionnaire measure: Eating Habits measure: Neurofilament light chain measure: Amyotrophic Lateral Sclerosis Functional Rating Scale Revised Prediction Model measure: Neurofilament Assess Score measure: Microtubule-associated protein 2 in serum measure: Microtubule-associated protein 2 in cerebrospinal fluid measure: Ubiquitin carboxy-terminal hydrolase L1 in serum measure: Ubiquitin carboxy-terminal hydrolase L1 in cerebrospinal fluid measure: Transmembrane glycoprotein NMB in serum measure: Transmembrane glycoprotein NMB in cerebrospinal fluid measure: Human cartilage glycoprotein 39 in serum measure: Human cartilage glycoprotein 39 in cerebrospinal fluid measure: SNAP-25 in serum measure: SNAP-25 in cerebrospinal fluid measure: Beta-synuclein in serum measure: Beta-synuclein in cerebrospinal fluid measure: Aquaporin-4 in serum measure: Aquaporin-4 in cerebrospinal fluid measure: Glial fibrillary acidic protein in serum measure: Glial fibrillary acidic protein in cerebrospinal fluid measure: Soluble triggering receptor expressed on myeloid cell-1 in serum measure: Soluble triggering receptor expressed on myeloid cell-1 in cerebrospinal fluid measure: CC-chemokine ligand 2 in serum measure: CC-chemokine ligand 2 in cerebrospinal fluid measure: interleukin-1b in serum measure: interleukin-1b in cerebrospinal fluid measure: interleukin-2 in serum measure: interleukin-2 in cerebrospinal fluid measure: interleukin-4 in serum measure: interleukin-4 in cerebrospinal fluid measure: interleukin-6 in serum measure: interleukin-6 in cerebrospinal fluid measure: interleukin-10 in serum measure: interleukin-10 in cerebrospinal fluid measure: interleukin-12p70 in serum measure: interleukin-12p70 in cerebrospinal fluid measure: interleukin-17 in serum measure: interleukin-17 in cerebrospinal fluid measure: Tumor necrosis factor alpha in serum measure: Tumor necrosis factor alpha in cerebrospinal fluid sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: RWTH Aachen city: Aachen country: Germany lat: 50.77664 lon: 6.08342 facility: Charité Universitätsmedizin Berlin city: Berlin country: Germany name: André Maier, Dr. role: CONTACT lat: 52.52437 lon: 13.41053 facility: University Clinic Bochum city: Bochum country: Germany lat: 51.48165 lon: 7.21648 facility: University Clinic Bonn city: Bonn country: Germany name: Patrick Weydt, Dr. role: CONTACT lat: 50.73438 lon: 7.09549 facility: Technical University Dresden city: Dresden country: Germany name: René Günther, Dr. role: CONTACT lat: 51.05089 lon: 13.73832 facility: University Clinic Erlangen city: Erlangen country: Germany name: Jürgen Winkler, Prof. Dr. role: CONTACT lat: 49.59099 lon: 11.00783 facility: Alfried Krupp Krankenhaus Essen city: Essen country: Germany name: Torsten Grehl, Dr. role: CONTACT lat: 51.45657 lon: 7.01228 facility: University Clinic Göttingen city: Göttingen country: Germany name: Jan C Koch, Dr. role: CONTACT lat: 51.53443 lon: 9.93228 facility: University Clinic Halle city: Halle country: Germany name: Elena Schlapakow, Dr. role: CONTACT lat: 51.48159 lon: 11.97948 facility: Hannover Medical School city: Hannover country: Germany name: Susanne Petri, Prof. Dr. role: CONTACT lat: 52.37052 lon: 9.73322 facility: University Clinic Jena city: Jena country: Germany name: Annekathrin Rödiger, Dr. role: CONTACT lat: 50.92878 lon: 11.5899 facility: DRK Clinic Kassel city: Kassel country: Germany name: Clemens Eickhoff, Dr. role: CONTACT lat: 51.31667 lon: 9.5 facility: Klinikum Kempten city: Kempten country: Germany name: Elmar Pinkhardt, Dr. role: CONTACT lat: 47.72674 lon: 10.31389 facility: University Clinic Leipzig city: Leipzig country: Germany name: Moritz Metelmann, Dr. role: CONTACT lat: 51.33962 lon: 12.37129 facility: University Clinic Lübeck city: Lübeck country: Germany name: Julian Großkreutz, Prof. Dr. role: CONTACT lat: 53.86893 lon: 10.68729 facility: University Clinic Mannheim city: Mannheim country: Germany name: Joachim Wolf, Dr. role: CONTACT lat: 49.4891 lon: 8.46694 facility: Technical University Munich city: Munich country: Germany name: Paul Lingor, Prof. Dr. role: CONTACT lat: 48.13743 lon: 11.57549 facility: University Clinic Münster city: Münster country: Germany name: Matthias Böntert, Dr. role: CONTACT lat: 51.96236 lon: 7.62571 facility: University Clinic Regensburg city: Regensburg country: Germany name: Zacharias Kohl, Dr. role: CONTACT lat: 49.01513 lon: 12.10161 facility: University Clinic Rostock city: Rostock country: Germany name: Johannes Prudlo, Prof. Dr. role: CONTACT name: Andreas Herrmann role: PRINCIPAL_INVESTIGATOR lat: 54.0887 lon: 12.14049 facility: University of Ulm city: Ulm country: Germany name: Johannes Dorst, Prof. Dr. role: CONTACT lat: 48.39841 lon: 9.99155 facility: DKD HELIOS Clinic Wiesbaden city: Wiesbaden country: Germany name: Bertold Schrank, Dr. role: CONTACT lat: 50.08258 lon: 8.24932 facility: University Clinic Würzburg city: Würzburg country: Germany name: Daniel Zeller, Dr. role: CONTACT lat: 49.79391 lon: 9.95121 hasResults: False
<\|newrecord\|> nctId: NCT06280066 id: 2023/607 briefTitle: An Intervention-Based Approach to Strengthen the Psychological Health of Children With Cystic Fibrosis and Their Mothers overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-06 date: 2024-09 date: 2024-02-28 date: 2024-04-17 name: Kirsehir Ahi Evran Universitesi class: OTHER name: TC Erciyes University briefSummary: Cystic fibrosis (CF) is a life-threatening exocrine gland disease that is often diagnosed in childhood, and its incidence tends to increase and affect physical and mental health.The purpose of this study is to evaluate the effectiveness of the Intervention Program Based on Strengthening the Psychological Resilience of Children Diagnosed with Cystic Fibrosis and Their Mothers, prepared for children with CF (8-12 years old) and their mothers.In the first stage, the CF experiences of children with cystic fibrosis and how they perceive these experiences will be examined with visual phenomenology, and their mothers' CF experiences and perceptions will be examined with phenomenology. In this regard, 10 children will be asked to draw pictures and their pictures will be analyzed. In-depth individual interviews will be held with mothers.In the 2nd stage, the effectiveness of the Intervention Program Based on Strengthening Psychological Resilience for Children Diagnosed with Cystic Fibrosis and Their Mothers will be determined with a pre-test-post-test randomized controlled experimental design.In the literature review, Gpower analysis was performed (α: 0.05, β: 0.99, d: 1.88) based on the results of studies conducted with children diagnosed with CF and their parents, similar to this study, and 15 samples were used for each group. It is planned to recruit people. Considering the possibility of data loss in the study, it was always deemed appropriate to include 22 people for the group. It was planned to sample a total of 88 children with CF and their mothers, 44 in the intervention group and 44 in the control group. In the 3rd stage, after the experiment, the participants' experiences regarding the intervention program will be examined through interviews and qualitative research method. Thus, qualitative interviews will be conducted before and after the experiment. Data will be collected using these tools: Children; Child and Mother Descriptive Characteristics Form, Semi-Structured Interview Form,Respiratory Function Test, Reorganized Cystic Fibrosis Questionnaire, Psychological Resilience Attitude and Skills Scale and Functional Disability Inventory; Mothers; The Revised Cystic Fibrosis Questionnaire, The Depression Anxiety and Stress Scale, Post-Traumatic Growth Scale and Brief Psychological Resilience Scale. Measurements will be taken before the intervention, after the intervention, at the 1st and 3rd months. conditions: Cystic Fibrosis conditions: Children conditions: Resilience,Psychological conditions: Laughter Yoga conditions: Laughter Therapy conditions: Mothers conditions: Psychological Health conditions: Lung Functions studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: PARTICIPANT count: 88 type: ESTIMATED name: Intervention Program Based on Strengthening the Psychological Resilience of Children Diagnosed with Cystic Fibrosis and Their Mothers measure: The Respiratory Function Test measure: The Revised Cystic Fibrosis Questionnaire Child Form measure: Psychological Resilience Attitude and Skills Scale Child Form measure: Functional Disability Inventory Child measure: The Revised Cystic Fibrosis Questionnaire Parent Form measure: Depression Anxiety and Stress Scale measure: Post-Traumatic Growth Scale measure: Brief Psychological Resilience Scale sex: ALL minimumAge: 8 Years maximumAge: 12 Years stdAges: CHILD facility: Erciyes University city: Kayseri zip: 38000 country: Turkey name: Selin Söyünmez role: CONTACT phone: +905319762180 email: [email protected] name: Yağmur Sezer Efe, PhD role: PRINCIPAL_INVESTIGATOR name: Selin Söyünmez, PhD Student role: PRINCIPAL_INVESTIGATOR name: Mehmet Köse, MD role: PRINCIPAL_INVESTIGATOR lat: 38.73222 lon: 35.48528 hasResults: False
<\|newrecord\|> nctId: NCT06280053 id: 103-3024A3 briefTitle: HealiAid in the Treatment of Different Wounds overallStatus: COMPLETED date: 2016-03-02 date: 2018-04-11 date: 2018-10-26 date: 2024-02-28 date: 2024-02-28 name: Maxigen Biotech Inc. class: INDUSTRY briefSummary: The goal of this open-label, post-market clinical follow-up study is to demonstrate the safety and effectiveness of HealiAid Collagen Wound Dressing in patients classified into different types of wounds: venous ulcers, bedsores, diabetic foot wounds and burn wounds.
The main questions it aims to answer are:
1. The wound healing which was defined as the percentage of area change.
2. The duration of wound healing.
3. The granulation tissue growth of the wound.
4. The wound exudate.
5. Safety Indicators of which incidences after treatment.
HealiAid will be applied to eligible subjects who will later be followed up for 12 weeks. conditions: Venous Ulcers conditions: Bedsores conditions: Diabetic Foot Wound conditions: Burn Wound studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: The patients' wound conditions were divided into four types: venous ulcers, bedsores, diabetic foot wounds and burn wounds. primaryPurpose: OTHER masking: NONE count: 18 type: ACTUAL name: HealiAid Collagen Wound Dressing measure: Wound Healing measure: Wound Healing measure: Duration of Wound Healing measure: Granulation Tissue Growth measure: Wound Exudate measure: Incidence of Safety Events sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<\|newrecord\|> nctId: NCT06280040 id: UM Longitudinal 1942/2022 briefTitle: Longitudinal Follow-Up of Patients Treated With Hypofractionated Stereotactic Photon Radiotherapy Due to Uveal Melanoma overallStatus: RECRUITING date: 2023-11-23 date: 2025-06-30 date: 2025-06-30 date: 2024-02-28 date: 2024-03-06 name: Medical University of Vienna class: OTHER briefSummary: The purpose of this study is to evaluate the incidence and severity of retinopathy and opticopathy one year after treatment with hypofractionated stereotactic photon radiotherapy due to uveal melanoma. Patients will be imaged before radiation, as well as 3, 6, 9 and 12 months after radiation using sonography funds photography, optical coherence tomography angiography, oximeter and microperimetry. conditions: Uveal Melanoma studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 20 type: ESTIMATED name: Clinical examination and multimodal ocular imaging measure: Incidence and Severity of Retinopathy measure: Incidence and Severity of Opticopathy measure: Functional Outcome measure: Incidence and Severity of Retinopathy and Opticopathy in oximeter sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Ophthalmology and Optometry, Medical University Vienna status: RECRUITING city: Vienna zip: 1090 country: Austria name: Judith Kreminger, MD role: CONTACT phone: 0043 1 40400 48470 email: [email protected] name: Reinhard Told, MD, PhD, Priv.-Doz. role: CONTACT phone: 0043 1 40400 48470 email: [email protected] name: Adrian Reumueller, MD, Priv.-Doz role: SUB_INVESTIGATOR name: Roman Dunavoelgyi, MD, Assoc.-Prof. role: SUB_INVESTIGATOR lat: 48.20849 lon: 16.37208 hasResults: False
<\|newrecord\|> nctId: NCT06280027 id: MUDHF_BK1 briefTitle: Effect of Midline Discrepancy and Crown Width Disporportion on Esthetics overallStatus: COMPLETED date: 2023-06-05 date: 2023-06-12 date: 2023-12-22 date: 2024-02-28 date: 2024-02-28 name: Marmara University class: OTHER briefSummary: In the web-based cross-sectional study 180 participants were included. Half of them (n = 90) were patients (laypeople) of the university clinic and the remaining half were restorative dentists and prosthodontists with similar levels of clinical experience (at least 3 years of academic training).
A frontal view full-face portrait image of a 25-year-old female was selected as a model for the study, with a smile exhibiting good dental alignment, a quite good midline position, and tooth size symmetry.
The original image was digitally modified by a single restorative instructor using Photoshop CC (Adobe, USA) software program. The modifications were divided into three parts. The first part was the generation of midline discrepancy at different levels. The midline was digitally moved to the right side of the patient 1 - 4 millimeters, gradually. The midline movement was performed together with the whole maxillary arch.
The second part was the generation of individual crown width disproportions. Accordingly, the mesiodistal width of the left central, lateral, and canine was digitally decreased one by one, gradually, while the width of the symmetrical teeth on the right side was simultaneously increased.
The third part was the generation of distributed crown width disproportions. Accordingly, the total mesiodistal width of the left central, lateral, and canine was equally decreased, gradually, while the total width of the symmetrical teeth on the right side was simultaneously increased.
In total, 15 images were displayed in random order to the participants including the original image. An online survey was generated to quantitatively evaluate the level of esthetic perception. Subsequently, the participants were asked to evaluate the level of smile esthetics of the presented random images, without being informed about the digital manipulations of the images. The participants were even not informed about the original image. They were expected to answer the question "How esthetic do you consider this smile?" The evaluation of each image was performed via a Visual analog scale VAS, ranging from point 0 (extremely not esthetic) to point 100 (extremely esthetic). conditions: Esthetics, Dental studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 180 type: ACTUAL name: survey measure: survey on midline discrepancy at different levels measure: survey on individual crown width disproportions measure: survey on distributed crown width disproportions sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Marmara University Faculty of Dentistry city: İstanbul zip: 34854 country: Turkey lat: 41.01384 lon: 28.94966 hasResults: False
<\|newrecord\|> nctId: NCT06280014 id: YYU-09/15.12.2021 briefTitle: Evaluation of the Effects of Mefenamic Acid and Dexketoprofen on Postoperative Wisdom Dental Surgery overallStatus: COMPLETED date: 2022-01-20 date: 2022-02-20 date: 2023-09-25 date: 2024-02-28 date: 2024-02-28 name: Yuzuncu Yıl University class: OTHER briefSummary: This study was administered to 22 female and 8 male patients. Patients with impacted wisdom teeth on both sides of the mandible were selected. After impacted tooth extraction, the patient used mefenamic acid on one side and dexketoprofen on the other side for postoperative pain relief. The effects of these two materials on patient comfort were investigated. conditions: Tooth, Impacted conditions: Tooth Diseases studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: SUPPORTIVE_CARE masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 30 type: ACTUAL name: Surgery of impacted mandibular wisdom teeth name: Surgery of impacted mandibular wisdom teeth measure: Mouth opening measurements measure: Facial edema measure: Visual Analog Scale sex: ALL minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT facility: Serap Keskin Tunc city: Van zip: 65100 country: Turkey lat: 38.49457 lon: 43.38323 hasResults: False
<\|newrecord\|> nctId: NCT06280001 id: 2023YFC2308802-04 briefTitle: A Multicenter Prospective Clinical Cohort Study on the Pathogen Spectrum of HIV/AIDS Complicated With Infection overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2026-11 date: 2026-11 date: 2024-02-28 date: 2024-03-04 name: Zhejiang University class: OTHER name: Beijing Ditan Hospital name: Beijing YouAn Hospital name: Huashan Hospital name: Qilu Hospital of Shandong University briefSummary: The goal of this observational study is to determine the incidence and spectrum of opportunistic infections among Chinese HIV/AIDS patients at this stage, to find intervention targets, to construct an early warning prediction model, and to give an individualized program with integrated immune function to obtain salvage opportunities for patients.The main questions it aims to answer are:
* Describe the populations and characteristics of pathogenic microorganisms involved in HIV co-infection, map the spatial and temporal changes in the infection system of pathogenic microorganisms, and evaluate their impact on disease regression.
* Explore the mechanism of interaction between pathogenic microorganisms and host autoimmune deficiencies.
* Discover early warning and predictive markers and immunological indicators of pathogenic microorganisms, and explore new technologies and programs to reduce the mortality rate of infection. conditions: Acquired Immunodeficiency Syndrome conditions: HIV Infections studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 500 type: ESTIMATED measure: Secondary infections in patients with HIV/AIDS at 4 weeks measure: quick SEPSIS RELATED ORGAN FAILURE ASSESSMENT(qSOFA) at 4 weeks measure: Survival rate sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<\|newrecord\|> nctId: NCT06279988 id: K24 briefTitle: BRING-UP 3 Heart Failure acronym: BRING-UP3HF overallStatus: RECRUITING date: 2023-09-15 date: 2026-06-30 date: 2026-07-30 date: 2024-02-28 date: 2024-02-28 name: Heart Care Foundation class: OTHER briefSummary: The aim of this observational study is to assess the level of adherence to guideline recommendations regarding the management of patients with Heart Failure with Reduced Ejection Fraction (HFrEF); - the safety profile of the implementation of recommended treatments; - to monitor treatment patterns of patients with acute hert failure (HF); - to monitor treatment patterns of all patients with chronic HF irrespective of the level of ejection fraction (EF). conditions: Heart Failure studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 10000 type: ESTIMATED measure: Rate of adherence to Guideline-Directed Medical Therapy (GDMTs) in HFrEF measure: Rate of patient achieving appropriate dosages of GDMTs measure: Treatment patterns of patients with Heart failure with mildly reduced ejection fraction (HFmrEF) and Heart failure with preserved ejection fraction (HFpEF) measure: Treatment patterns of patients with Acute Heart Failure (AHF) irrespective of the level of EF measure: All cause and specific causes of death and hospitalization (Exploratory endpoint) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ospedale Santo Spirito - Sc Cardiologia status: RECRUITING city: Casale Monferrato state: AL zip: 15033 country: Italy name: FEDERICO NARDI, MD role: CONTACT lat: 45.13338 lon: 8.4525 facility: Ospedale San Giacomo - Sc Cardiologia status: RECRUITING city: Novi Ligure state: AL zip: 15067 country: Italy name: MARIA E ROVERE, MD role: CONTACT lat: 44.76246 lon: 8.787 facility: Ospedali Riuniti - Sod Cardiologia Ospedaliera E Utic status: RECRUITING city: Ancona state: AN zip: 60122 country: Italy name: ILARIA BATTISTONI, MD role: CONTACT lat: 43.5942 lon: 13.50337 facility: Irccs Inrca - Uo Cardiologia/Utic/Telecardiologia status: RECRUITING city: Ancona state: AN zip: 60131 country: Italy name: PAOLA TAMBURRINI, MD role: CONTACT lat: 43.5942 lon: 13.50337 facility: Ospedale San Donato - U.O.C Cardiologia status: RECRUITING city: Arezzo state: AR zip: 52100 country: Italy name: MATTEO ROCCO RECCIA, MD role: CONTACT lat: 43.46276 lon: 11.88068 facility: Ospedale Valdichiana Santa Margherita - Uosd Cardiologia S.O. Cortona status: RECRUITING city: Cortona state: AR zip: 52044 country: Italy name: SIMONA D'ORAZIO, MD role: CONTACT lat: 43.27467 lon: 11.98533 facility: Aorn San Giuseppe Moscati - U.O. Cardiologia/Utic 'D. Rotiroti' status: RECRUITING city: Avellino state: AV zip: 83100 country: Italy name: EMILIO DI LORENZO, MD role: CONTACT lat: 40.91494 lon: 14.79103 facility: Ospedale Miulli - U.O.C. Cardiologia - Utic status: RECRUITING city: Acquaviva Delle Fonti state: BA zip: 70021 country: Italy name: NICOLA VITULANO, MD role: CONTACT lat: 40.89704 lon: 16.8433 facility: Ospedale Della Murgia - Fabio Perinei - S.C. Cardiologia-Utic status: RECRUITING city: Altamura state: BA zip: 70022 country: Italy name: PIETRO SCICCHITANO, MD role: CONTACT lat: 40.82664 lon: 16.54952 facility: Ospedale San Paolo - Cardiologia-Utic status: RECRUITING city: Bari state: BA zip: 70123 country: Italy name: PASQUALE CALDAROLA, MD role: CONTACT lat: 41.11148 lon: 16.8554 facility: Ics Maugeri Spa Societa' Benefit Irccs Bari - Cardiologia Riabilitativa status: RECRUITING city: Bari state: BA zip: 70124 country: Italy name: ANDREA PASSANTINO, MD role: CONTACT lat: 41.11148 lon: 16.8554 facility: Mater Dei Hospital - Riabilitazione Cardiologica status: RECRUITING city: Bari state: BA zip: 70124 country: Italy name: ROCCO LAGIOIA, MD role: CONTACT lat: 41.11148 lon: 16.8554 facility: Ospedale Di Venere - U.O.C. Di Cardiologia status: RECRUITING city: Carbonara Di Bari state: BA zip: 70012 country: Italy name: MASSIMO V BONFANTINO, MD role: CONTACT lat: 41.06667 lon: 16.86667 facility: Ospedale San Giacomo - Uoc Cardiologia status: RECRUITING city: Monopoli state: BA zip: 70043 country: Italy name: ONOFRIO ROSSI, MD role: CONTACT lat: 40.94918 lon: 17.29717 facility: Ospedale Degli Infermi - Sc Di Cardiologia status: RECRUITING city: Ponderano state: BI zip: 13875 country: Italy name: ANDREA ROGNONI, MD role: CONTACT lat: 45.53846 lon: 8.05592 facility: Presidio Ospedaliero "Santa Maria Del Prato" - U.O.C. Di Cardiologia-Utic status: RECRUITING city: Feltre state: BL zip: 32032 country: Italy name: FRANCESCA DE CIAN, MD role: CONTACT lat: 46.02085 lon: 11.90031 facility: Ospedale Di Bentivoglio - U.O. Cardiologia Pianura status: RECRUITING city: Bentivoglio state: BO zip: 40010 country: Italy name: GIANFRANCO TORTORICI, MD role: CONTACT lat: 44.6369 lon: 11.41737 facility: Ospedale Maggiore - U.O.C. Di Cardiologia status: RECRUITING city: Bologna state: BO zip: 40133 country: Italy name: GIULIA BUGANI, MD role: CONTACT lat: 44.49381 lon: 11.33875 facility: Ospedale Policlinico S. Orsola-Malpighi - Medicina Interna - Borghi status: RECRUITING city: Bologna state: BO zip: 40138 country: Italy name: CLAUDIO BORGHI, MD role: CONTACT lat: 44.49381 lon: 11.33875 facility: Ospedale Perrino - U.O.C. Di Cardiologia status: RECRUITING city: Brindisi state: BR zip: 72100 country: Italy name: GIAN PAOLO GIORDA, MD role: CONTACT lat: 40.63215 lon: 17.93607 facility: Istituto Ospedaliero Fondazione Poliambulanza - Unita Operativa Di Cardiologia E Utic status: RECRUITING city: Brescia state: BS zip: 25124 country: Italy name: LORENZO CAPRINI, MD role: CONTACT lat: 45.53558 lon: 10.21472 facility: Ospedale Di Desenzano Del Garda - Divisione Di Cardiologia - U.C.C. status: RECRUITING city: Desenzano Del Garda state: BS zip: 25015 country: Italy name: GIOSUE' MASCIOLI, MD role: CONTACT lat: 45.47127 lon: 10.53559 facility: Ospedale Civile 'La Memoria' - U.O. Di Cardiologia status: RECRUITING city: Gavardo state: BS zip: 25085 country: Italy name: MARCO TRIGGIANI, MD role: CONTACT lat: 45.58939 lon: 10.44257 facility: Istituti Clinici Scientifici Maugeri Irccs Sede Di Lumezzane - U.O. Di Cardiologia Riabilitativa status: RECRUITING city: Lumezzane state: BS zip: 25065 country: Italy name: EMANUELA ZANELLI, MD role: CONTACT lat: 45.64789 lon: 10.26487 facility: Ospedale Monsignor Angelo R. Di Miccoli - Uoc Cardiologia/Utic status: ACTIVE_NOT_RECRUITING city: Barletta state: BT zip: 76121 country: Italy lat: 41.31429 lon: 16.28165 facility: Ospedale Caduti in Guerra - U.O.S.V.D Di Riabilitazione Cardiologica status: RECRUITING city: Canosa Di Puglia state: BT zip: 76012 country: Italy name: FRANCESCO BARTOLOMUCCI, MD role: CONTACT lat: 41.21954 lon: 16.06768 facility: Ospedale Centrale Bolzano - Cardiologia E Prove Funzionali status: RECRUITING city: Bolzano state: BZ zip: 39100 country: Italy name: PRISCILLA MILEWSKI, MD role: CONTACT lat: 46.49067 lon: 11.33982 facility: Azienda Ospedaliera S. Anna E S. Sebastiano - U.O. Cardiologia D'Emergenza Con Utic status: RECRUITING city: Caserta state: CE zip: 81100 country: Italy name: PAOLO CALABRO', MD role: CONTACT lat: 41.07262 lon: 14.33231 facility: Villa Delle Magnolie - Riabilitazione Cardiologica status: RECRUITING city: Castel Morrone state: CE zip: 81020 country: Italy name: FRANCESO PERONE, MD role: CONTACT lat: 41.12102 lon: 14.35473 facility: Casa Di Cura San Michele - Uo Cardiologia status: RECRUITING city: Maddaloni state: CE zip: 81024 country: Italy name: MARCO PEPE, MD role: CONTACT lat: 41.03578 lon: 14.3823 facility: Ospedale Policlinico Ss. Annunziata - Uoc Cardiologia-Utic status: RECRUITING city: Chieti state: CH zip: 66013 country: Italy name: MARCO ZIMARINO, MD role: CONTACT lat: 42.34827 lon: 14.16494 facility: Azienda Ospedaliera Santa Croce E Carle - Sc Cardiologia status: RECRUITING city: Cuneo state: CN zip: 12100 country: Italy name: ROBERTA ROSSINI, MD role: CONTACT lat: 44.39071 lon: 7.54828 facility: Ospedale Regina Montis Regalis - U.O. Cardiologia-Utic status: RECRUITING city: Mondovì state: CN zip: 12084 country: Italy name: MAURO FEOLA, MD role: CONTACT lat: 44.39603 lon: 7.81764 facility: Ospedale Maggiore Ss. Annunziata - Sc Cardiologia status: RECRUITING city: Savigliano state: CN zip: 12038 country: Italy name: MICHELE DE BENEDICTIS, MD role: CONTACT lat: 44.64808 lon: 7.65677 facility: Ospedale Pietro E Michele Ferrero - Cardiologia E Utic status: RECRUITING city: Verduno state: CN zip: 12060 country: Italy name: VIRGINIA BOVOLO, MD role: CONTACT lat: 44.66614 lon: 7.93074 facility: Ospedale S. Anna - U.O.C. Di Cardiologia status: RECRUITING city: San Fermo Della Battaglia state: CO zip: 22020 country: Italy lat: 45.80868 lon: 9.04744 facility: Ospedale Oglio Po - U.O. Di Cardiologia-Utic status: RECRUITING city: Casalmaggiore state: CR zip: 26041 country: Italy name: CARLO PISCICELLI, MD role: CONTACT lat: 44.98981 lon: 10.42055 facility: Ospedale Civile Ferrari - U.O.C. Cardiologia-Utic status: RECRUITING city: Castrovillari state: CS zip: 87012 country: Italy name: ANDREA MADEO, MD role: CONTACT lat: 39.81632 lon: 16.20183 facility: Ospedale Spoke Paola- Cetraro Po Paola - Utic Cardiologia status: RECRUITING city: Paola state: CS zip: 87027 country: Italy name: MARIA T MANES, MD role: CONTACT lat: 39.36313 lon: 16.03691 facility: P.O. Garibaldi-Nesima - Arnas Garibaldi - U.O.C. Di Cardiologia Con Utic status: RECRUITING city: Catania state: CT zip: 95122 country: Italy name: MICHELE M GULIZIA, MD role: CONTACT lat: 37.49223 lon: 15.07041 facility: Policlinico Catania Po G. Rodolico - Cardiologia Utic status: RECRUITING city: Catania state: CT zip: 95125 country: Italy name: GIUSEPPE LEONARDI, MD role: CONTACT lat: 37.49223 lon: 15.07041 facility: Azienda Ospedaliera Cannizzaro - Uoc Cardiologia status: RECRUITING city: Catania state: CT zip: 95126 country: Italy name: FRANCESCO AMICO, MD role: CONTACT lat: 37.49223 lon: 15.07041 facility: P.O. "Materdomini" - A.O.U. "Renato Dulbecco" - Ssd Cardiologia Riabilitativa status: RECRUITING city: Catanzaro state: CZ zip: 88100 country: Italy name: DOMENICO ZUCCO, MD role: CONTACT lat: 38.88247 lon: 16.60086 facility: P.O. "Pugliese" - A.O.U. "Renato Dulbecco" - Utic-Emodinamica E Cardiologia Interventistica status: RECRUITING city: Catanzaro state: CZ zip: 88100 country: Italy name: FRANCESCO CASSADONTE, MD role: CONTACT lat: 38.88247 lon: 16.60086 facility: Presidio Ospedaliero Umberto I - Cardiologia - Utic- Riabilitazione status: RECRUITING city: Enna state: EN zip: 94100 country: Italy name: RAFFAELLA IUDICELLO, MD role: CONTACT lat: 37.5655 lon: 14.27433 facility: Ospedale G.B. Morgagni - L. Pierantoni - U.O. Cardiologia status: RECRUITING city: Forli' state: FC zip: 47121 country: Italy name: ELISA GARDINI, MD role: CONTACT lat: 44.22177 lon: 12.04144 facility: Ospedale Ss. Annunziata - U.O. Di Cardiologia Provinciale status: RECRUITING city: Cento state: FE zip: 44042 country: Italy name: BIAGIO SASSONE, MD role: CONTACT lat: 44.73099 lon: 11.28716 facility: Arcispedale Sant'Anna - U.O. Cardiologia status: RECRUITING city: Ferrara state: FE zip: 44124 country: Italy name: ALESSANDRO FUCILI, MD role: CONTACT lat: 44.83804 lon: 11.62057 facility: Ospedale Del Delta - U.O. Cardiologia status: RECRUITING city: Lagosanto state: FE zip: 44023 country: Italy name: BIAGIO SASSONE, MD role: CONTACT lat: 44.76282 lon: 12.14005 facility: Policlinico Riuniti - S.C. Di Cardiologia Universitaria-Utic status: RECRUITING city: Foggia state: FG zip: 71100 country: Italy name: NATALE D BRUNETTI, MD role: CONTACT lat: 41.45845 lon: 15.55188 facility: Ospedale Casa Sollievo Della Sofferenza - Cardiologia - Utic - Riabil Cardiologica status: ACTIVE_NOT_RECRUITING city: San Giovanni Rotondo state: FG zip: 71013 country: Italy lat: 41.70643 lon: 15.7277 facility: Ospedale San Giuseppe - Cardiologia status: RECRUITING city: Empoli state: FI zip: 50053 country: Italy name: FLAVIO VENTURI, MD role: CONTACT lat: 43.71795 lon: 10.94758 facility: Ospedale Santa Maria Nuova - Cardiologia status: RECRUITING city: Firenze state: FI zip: 50122 country: Italy name: MASSIMO MILLI, MD role: CONTACT lat: 43.77925 lon: 11.24626 facility: Ospedale San Giovanni Di Dio - Sos Cardiologia status: RECRUITING city: Firenze state: FI zip: 50124 country: Italy name: MASSIMO MILLI, MD role: CONTACT lat: 43.77925 lon: 11.24626 facility: Aou Careggi - Geriatria - Utig status: RECRUITING city: Firenze state: FI zip: 50141 country: Italy name: ANDREA UNGAR, MD role: CONTACT lat: 43.77925 lon: 11.24626 facility: Ospedale Padre Antero Micone - Sc Cardiologia - Utic status: RECRUITING city: Genova state: GE zip: 16100 country: Italy name: SILVIA COSTA, MD role: CONTACT lat: 44.40478 lon: 8.94438 facility: Irccs Ospedale Policlinico San Martino - Clinica Malattie Apparato Cardiovascolare status: RECRUITING city: Genova state: GE zip: 16132 country: Italy name: MARCO CANEPA, MD role: CONTACT lat: 44.40478 lon: 8.94438 facility: Ospedale Del Tigullio Polo Lavagna - Sc Cardiologia E Utic status: RECRUITING city: Lavagna state: GE zip: 16033 country: Italy name: GUIDO PARODI, MD role: CONTACT lat: 44.3062 lon: 9.35383 facility: Ospedale San Giovanni Di Dio - Sc Cardiologia (Gorizia-Monfalcone) status: RECRUITING city: Gorizia state: GO zip: 34170 country: Italy name: GERARDINA LARDIERI, MD role: CONTACT lat: 45.94088 lon: 13.62167 facility: Ospedale Civile San Polo - Sc Cardiologia (Gorizia-Monfalcone) status: RECRUITING city: Monfalcone state: GO zip: 34074 country: Italy name: GERARDINA LARDIERI, MD role: CONTACT lat: 45.80463 lon: 13.53292 facility: Ospedale S. Andrea - Alta Maremma - Uosd Cardiologia status: RECRUITING city: Massa Marittima state: GR zip: 58024 country: Italy name: NICOLA D'APRILE, MD role: CONTACT lat: 43.04779 lon: 10.89293 facility: Ospedale Alessandro Manzoni - S.C. Di Cardiologia status: RECRUITING city: Lecco state: LC zip: 23900 country: Italy name: ROBERTO SPOLADORE, MD role: CONTACT lat: 45.85589 lon: 9.39704 facility: Ospedale San Giuseppe Da Copertino - U.O. Di Cardiologia status: ACTIVE_NOT_RECRUITING city: Copertino state: LE zip: 73043 country: Italy lat: 40.26821 lon: 18.0543 facility: Ospedale Vito Fazzi - Uoc Cardiologia-Utic Ed Emodinamica status: RECRUITING city: Lecce state: LE zip: 73100 country: Italy name: STEFANIA MARAZIA, MD role: CONTACT lat: 40.35481 lon: 18.17244 facility: Ospedale Ignazio Veris Delli Ponti - Uoc Cardiologia-Utic "E. Vilei" status: RECRUITING city: Scorrano state: LE zip: 73020 country: Italy name: COSIMO A GRECO, MD role: CONTACT lat: 40.09018 lon: 18.29993 facility: Ospedali Riuniti - U.O.C. Cardiologia E Utic status: RECRUITING city: Livorno state: LI zip: 57124 country: Italy name: EMILIO M PASANISI, MD role: CONTACT lat: 43.54427 lon: 10.32615 facility: Ospedale Villamarina - Cardiologia E Utic Piombino Elba status: RECRUITING city: Piombino state: LI zip: 57025 country: Italy name: LARA FREDIANI, MD role: CONTACT lat: 42.92554 lon: 10.52585 facility: Nuovo Ospedale Versilia - Sc Cardiologia status: RECRUITING city: Camaiore state: LU zip: 55041 country: Italy name: GIANCARLO CASOLO, MD role: CONTACT lat: 43.94265 lon: 10.29754 facility: Ospedale Santa Croce - Uosd Cardiologia E Di Continuita Assist. status: ACTIVE_NOT_RECRUITING city: Castelnuovo Di Garfagnana state: LU zip: 55032 country: Italy lat: 44.1126 lon: 10.40518 facility: Ospedale Pio Xi - U.O.C. Di Cardiologia status: RECRUITING city: Desio state: MB zip: 20832 country: Italy name: FELICE ACHILLI, MD role: CONTACT lat: 45.61831 lon: 9.20249 facility: Policlinico Di Monza - Cardiologia Clinica E Utic status: RECRUITING city: Monza state: MB zip: 20900 country: Italy name: MATTEO OLDANI, MD role: CONTACT lat: 45.58005 lon: 9.27246 facility: Nuovo Ospedale Di Vimercate - S.C. Cardiologia E Utic status: RECRUITING city: Vimercate state: MB zip: 20871 country: Italy name: ANTONIO CIRO', MD role: CONTACT lat: 45.61545 lon: 9.36801 facility: Ospedale Generale Provinciale - U.O. Cardiologia status: RECRUITING city: Macerata state: MC zip: 62100 country: Italy name: DANIELE CONTADINI, MD role: CONTACT lat: 43.29789 lon: 13.45293 facility: Irccs Centro Neurolesi Bonino Pulejo - P.O Piemonte - Cardiologia E Utic status: RECRUITING city: Messina state: ME zip: 98124 country: Italy name: MYRIAM D'ANGELO, MD role: CONTACT lat: 38.19394 lon: 15.55256 facility: Azienda Ospedaliera Papardo - U.O. Cardiologia Con Utic - Emodinamica status: RECRUITING city: Messina state: ME zip: 98158 country: Italy name: MARIA C TODARO, MD role: CONTACT lat: 38.19394 lon: 15.55256 facility: Asst Papa Giovanni Xxiii - Sc Cardiologia 1 status: RECRUITING city: Bergamo state: MI zip: 24127 country: Italy name: EMILIA D'ELIA, MD role: CONTACT lat: 45.69601 lon: 9.66721 facility: Ospedale Di Cernusco Sul Naviglio - U. O. Di Cardiologia E Ucc status: RECRUITING city: Cernusco Sul Naviglio state: MI zip: 20063 country: Italy name: SERGIO SALA, MD role: CONTACT lat: 45.52526 lon: 9.33297 facility: Ospedale Edoardo Bassini - Sc Cardiologia-Ucc Asst Nord Milano (Bassini-Ssg) status: RECRUITING city: Cinisello Balsamo state: MI zip: 20092 country: Italy name: GRAZIA M CASTELLI, MD role: CONTACT lat: 45.55823 lon: 9.21495 facility: Asst Ovest Milanese - Po Di Legnano - Cardiologia E Unita' Coronarica status: RECRUITING city: Legnano state: MI zip: 20025 country: Italy name: CORINNA A INSERRA, MD role: CONTACT lat: 45.59788 lon: 8.91506 facility: Fondazione Irccs Ca' Granda Ospedale Maggiore Policlinico - Uoc Malattie Cardiovascolari status: RECRUITING city: Milano state: MI zip: 20122 country: Italy name: STEFANO CARUGO, MD role: CONTACT lat: 45.46427 lon: 9.18951 facility: Ospedale Fatebenefratelli E Oftalmico - Cardiologia E U.C.C. status: RECRUITING city: Milano state: MI zip: 20122 country: Italy name: ADA F GIGLIO, MD role: CONTACT lat: 45.46427 lon: 9.18951 facility: Centro Cardiologico Monzino Irccs - Scompenso,Cardiologia Clinica status: RECRUITING city: Milano state: MI zip: 20138 country: Italy name: PIETRO PALERMO, MD role: CONTACT lat: 45.46427 lon: 9.18951 facility: Istituti Clinici Scientifici Maugeri Irccs Sede Di Milano - Riabilitazione Cardiologica status: RECRUITING city: Milano state: MI zip: 20138 country: Italy name: MAURO MONELLI, MD role: CONTACT lat: 45.46427 lon: 9.18951 facility: Istituti Clinici Scientifici Maugeri Irccs Sede Di Milano - Uo Cure Subacute status: RECRUITING city: Milano state: MI zip: 20138 country: Italy name: MAURO PROIETTI, MD role: CONTACT lat: 45.46427 lon: 9.18951 facility: ASST SANTI PAOLO E CARLO - PO San Carlo - CARDIOLOGIA-UCC status: RECRUITING city: Milano state: MI zip: 20153 country: Italy name: STEFANO LUCREZIOTTI, MD role: CONTACT lat: 45.46427 lon: 9.18951 facility: Irccs Ospedale Galeazzi - Sant'Ambrogio - Cardiologia Universitaria Ed Imaging Cardiaco status: RECRUITING city: Milano state: MI zip: 20157 country: Italy name: EDOARDO CONTE, MD role: CONTACT lat: 45.46427 lon: 9.18951 facility: Asst Ospedale Metropolitano Niguarda - Cardiologia 2 - Insufficienza Cardiaca E Trapianto status: RECRUITING city: Milano state: MI zip: 20162 country: Italy name: ANDREA GARASCIA, MD role: CONTACT lat: 45.46427 lon: 9.18951 facility: Clinica San Carlo - U.O. Cardiologia-Unita'Cure Coronariche status: RECRUITING city: Paderno Dugnano state: MI zip: 20037 country: Italy name: ALESSIO CAPPELLERI, MD role: CONTACT lat: 45.56899 lon: 9.16483 facility: Presidio Ospedaliero Di Passirana - Cardiologia Riabilitativa status: RECRUITING city: Passirana state: MI zip: 20017 country: Italy name: ANNA FRISINGHELLI, MD role: CONTACT lat: 45.54792 lon: 9.04412 facility: Istituto Clinico Humanitas - Irccs - Cardiologia Clinica, Interventistica E Ucc status: RECRUITING city: Rozzano state: MI zip: 20089 country: Italy name: GIUSEPPE PINTO, MD role: CONTACT lat: 45.38193 lon: 9.1559 facility: Irccs Policlinico San Donato - U.O. Cardiologia Con Utic status: RECRUITING city: San Donato Milanese state: MI zip: 20097 country: Italy name: MASSIMO PIEPOLI, MD role: CONTACT lat: 45.41047 lon: 9.26838 facility: Irccs Policlinico Multimedica - Uo Di Cardiologia status: RECRUITING city: Sesto San Giovanni state: MI zip: 20099 country: Italy name: GIUSEPPE GALATI, MD role: CONTACT lat: 45.53329 lon: 9.22585 facility: Ospedale Madonna Delle Grazie - Ssd Utic status: ACTIVE_NOT_RECRUITING city: Matera state: Mount zip: 75100 country: Italy lat: 40.66599 lon: 16.60463 facility: Ospedale Giovanni Paolo Ii - Uosd Utic status: RECRUITING city: Policoro state: Mount zip: 75025 country: Italy name: ANDREA ANDRIANI, MD role: CONTACT lat: 40.2128 lon: 16.67795 facility: Ospedale Santa Maria Bianca - U.O. Di Cardiologia status: RECRUITING city: Mirandola state: MO zip: 41037 country: Italy name: BENEDETTA VERONESI, MD role: CONTACT lat: 44.88515 lon: 11.06902 facility: Ospedale Di Sassuolo - Cardiologia status: RECRUITING city: Sassuolo state: MO zip: 41049 country: Italy name: ANNA MARTELLI, MD role: CONTACT lat: 44.5432 lon: 10.7848 facility: Ospedale Giovanni Paolo Ii - Utic - Cardiologia status: RECRUITING city: Olbia state: OT zip: 07026 country: Italy name: MARIA ELENA L PICOI, MD role: CONTACT lat: 40.92337 lon: 9.49802 facility: Fondazione G. Giglio - U.O. Di Cardiologia status: RECRUITING city: Cefalu' state: PA zip: 90015 country: Italy name: TOMMASO A CIPOLLA, MD role: CONTACT lat: 38.03856 lon: 14.02285 facility: Ospedale Buccheri La Ferla Fatebenefratelli - Ssd Riabilitazione Cardiovascolare status: RECRUITING city: Palermo state: PA zip: 90123 country: Italy name: FILIPPO M SARULLO, MD role: CONTACT lat: 38.13205 lon: 13.33561 facility: Arnas P.O. Civico E Benfratelli - Uoc Utic status: RECRUITING city: Palermo state: PA zip: 90127 country: Italy name: IGNAZIO M SMECCA, MD role: CONTACT lat: 38.13205 lon: 13.33561 facility: Arnas P.O. Civico E Benfratelli - Uosd Cardiologia Clinica Trattam. Scompenso Card. status: RECRUITING city: Palermo state: PA zip: 90127 country: Italy name: EGLE INCALCATERRA, MD role: CONTACT lat: 38.13205 lon: 13.33561 facility: Maria Eleonora Hospital - Cardiologia status: RECRUITING city: Palermo state: PA zip: 90135 country: Italy name: VINCENZO PERNICE, MD role: CONTACT lat: 38.13205 lon: 13.33561 facility: Aor Villa Sofia-Cervello P.O. Cervello - U.O. Cardiologia - Cervello status: RECRUITING city: Palermo state: PA zip: 90146 country: Italy name: VINCENZO POLIZZI, MD role: CONTACT lat: 38.13205 lon: 13.33561 facility: Aor Villa Sofia-Cervello Po Villa Sofia - Uoc Cardiologia E Utic E Emodinamica -Villa Sofia status: RECRUITING city: Palermo state: PA zip: 90146 country: Italy name: AGATA M FLORESTA, MD role: CONTACT lat: 38.13205 lon: 13.33561 facility: Ospedale Unico Della Val Tidone - Cardiologia E Riabilitazione status: RECRUITING city: Castel San Giovanni state: PC zip: 29015 country: Italy name: GIANLUCA LANATI, MD role: CONTACT lat: 45.06014 lon: 9.43784 facility: Ospedale Civile 'Guglielmo Da Saliceto' - Uoc Cardiologia E Utic status: RECRUITING city: Piacenza state: PC zip: 29100 country: Italy name: DANIELA ASCHIERI, MD role: CONTACT lat: 45.05242 lon: 9.69342 facility: Ospedali Riuniti Padova Sud - U.O.C. Cardiologia status: RECRUITING city: Monselice state: PD zip: 35043 country: Italy name: FRANCESCA E BOVOLATO, MD role: CONTACT lat: 45.239 lon: 11.74984 facility: Ospedale Civile Dello Spirito Santo - Cardiologia Con Utic status: RECRUITING city: Pescara state: PE zip: 65124 country: Italy name: MASSIMO DI MARCO, MD role: CONTACT lat: 42.4584 lon: 14.20283 facility: Presidio Ospedaliero Citta' Di Castello - U.O. Cardiologia/Utic status: RECRUITING city: Citta' Di Castello state: PG zip: 06012 country: Italy name: KWAME MBOUMI, MD role: CONTACT lat: 43.46556 lon: 12.2375 facility: Nuovo Ospedale San Giovanni Battista - S.C. Cardiologia status: RECRUITING city: Foligno state: PG zip: 06034 country: Italy name: EMILIA BISCOTTINI, MD role: CONTACT lat: 42.95488 lon: 12.70268 facility: Ospedale Gubbio-Gualdo Tadino - U.O. Di Utic E Cardiologia status: RECRUITING city: Gubbio state: PG zip: 06024 country: Italy name: DEBORAH COSMI, MD role: CONTACT lat: 43.34996 lon: 12.57309 facility: Centro Servizi Grocco - Cardiologia Riabilitativa E Prevenzione status: RECRUITING city: Perugia state: PG zip: 06123 country: Italy name: LUCIA FILIPPUCCI, MD role: CONTACT lat: 43.1122 lon: 12.38878 facility: Ftgm - Stabilimento Di Pisa - Cardiologia E Medicina Cardiovascolare status: RECRUITING city: Pisa state: PI zip: 56124 country: Italy name: MICHELE EMDIN, MD role: CONTACT lat: 43.70853 lon: 10.4036 facility: Ospedale Generale Provinciale Lotti - U.O. Malattie Cardiovascolari Vde E Avc status: ACTIVE_NOT_RECRUITING city: Pontedera state: PI zip: 56025 country: Italy lat: 43.66141 lon: 10.63067 facility: Ospedale Di S. Vito Al Tagliamento - Ssd Cardiologia San Vito - Spilimbergo status: RECRUITING city: San Vito Al Tagliamento state: PN zip: 33078 country: Italy name: ARIANNA GARDIN, MD role: CONTACT lat: 45.9168 lon: 12.85945 facility: Ospedale San Jacopo - Soc Cardiologia status: RECRUITING city: Pistoia state: Point zip: 51100 country: Italy name: MICHELA TAGLIOLI, MD role: CONTACT lat: 43.93064 lon: 10.92365 facility: Ospedale Civile - U.O.C. Cardiologia - Utic status: RECRUITING city: Fidenza state: PR zip: 43036 country: Italy name: GIOVANNI TORTORELLA, MD role: CONTACT lat: 44.86694 lon: 10.06039 facility: Fondazione Irccs Policlinico San Matteo - Uoc Cardiologia 1 status: RECRUITING city: Pavia state: PV zip: 27100 country: Italy name: ANNALISA TURCO, MD role: CONTACT lat: 45.19205 lon: 9.15917 facility: Istituti Clinici Scientifici Maugeri Irccs Sede Di Pavia - U.O. Di Riabilitazione Cardiologica status: RECRUITING city: Pavia state: PV zip: 27100 country: Italy name: GIOVANNI FORNI, MD role: CONTACT lat: 45.19205 lon: 9.15917 facility: Ospedale Civile - U.O. Di Cardiologia status: RECRUITING city: Voghera state: PV zip: 27058 country: Italy name: MICHELA G COCCIA, MD role: CONTACT lat: 44.99151 lon: 9.01175 facility: Ospedale Civile - Uo Servizio Cardiologia status: RECRUITING city: Lugo state: RA zip: 48022 country: Italy name: GIULIA RICCI LUCCHI, MD role: CONTACT lat: 44.42137 lon: 11.91094 facility: Ospedale Civile Santa Maria Delle Croci - Uoc Cardiologia status: RECRUITING city: Ravenna state: RA zip: 48121 country: Italy name: ANDREA RUBBOLI, MD role: CONTACT lat: 44.41344 lon: 12.20121 facility: Ospedale Civile Di Guastalla - Sos Cardiologia E Riabilitazione Card Area Nord status: RECRUITING city: Guastalla state: RE zip: 42016 country: Italy name: ALESSANDRO NAVAZIO, MD role: CONTACT lat: 44.91172 lon: 10.66186 facility: Po Santa Maria Nuova - Ausl Re Irccs - Soc Cardiologia Ospedaliera status: RECRUITING city: Reggio Emilia state: RE zip: 42100 country: Italy name: ALESSANDRO NAVAZIO, MD role: CONTACT lat: 44.69825 lon: 10.63125 facility: Ospedale Riccardo Guzzardi - U.O.C. Di Cardiologia-Utic status: RECRUITING city: Vittoria state: RG zip: 97019 country: Italy name: GIUSEPPE DI STABILE, MD role: CONTACT lat: 36.95151 lon: 14.52788 facility: P.O. San Camillo de Lellis - U.O.C. Cardiologia status: RECRUITING city: Rieti state: RI zip: 02100 country: Italy name: AMIR KOL, MD role: CONTACT lat: 42.40476 lon: 12.85735 facility: Ospedale Dei Castelli - U.O.C. Di Cardiologia E Utic status: RECRUITING city: Ariccia state: RM zip: 00072 country: Italy name: ANNA R FELICI, MD role: CONTACT lat: 41.72063 lon: 12.6723 facility: Ospedale Civile San Paolo - U.O.C. Cardiologia - Utic status: RECRUITING city: Civitavecchia state: RM zip: 00053 country: Italy name: SERGIO CALCAGNO, MD role: CONTACT lat: 42.09325 lon: 11.79674 facility: Campus Biomedico - Cardiologia status: RECRUITING city: Roma state: RM zip: 00128 country: Italy name: FRANCESCA GRIGIONI, MD role: CONTACT lat: 41.89193 lon: 12.51133 facility: P.O. San Filippo Neri - Asl Roma 1 - Cardiologia Clinica E Riabilitativa status: RECRUITING city: Roma state: RM zip: 00135 country: Italy name: FURIO COLIVICCHI, MD role: CONTACT lat: 41.89193 lon: 12.51133 facility: Inmi Lazzaro Spallanzani Irccs - Servizio Di Cardiologia Del Dipartimento Clinico status: RECRUITING city: Roma state: RM zip: 00149 country: Italy name: MARIA C GATTO, MD role: CONTACT lat: 41.89193 lon: 12.51133 facility: Ospedale San Camillo - Uoc Cardiologia status: RECRUITING city: Roma state: RM zip: 00152 country: Italy name: GIOVANNI PULIGNANO, MD role: CONTACT lat: 41.89193 lon: 12.51133 facility: Ospedale Sandro Pertini - Uoc Cardiologia status: RECRUITING city: Roma state: RM zip: 00157 country: Italy name: ANTONINO GRANATELLI, MD role: CONTACT lat: 41.89193 lon: 12.51133 facility: Policlinico Casilino - U.O.C. Cardiologia status: RECRUITING city: Roma state: RM zip: 00169 country: Italy name: LEONARDO CALO', MD role: CONTACT lat: 41.89193 lon: 12.51133 facility: Ao San Giovanni Addolorata - Uoc Cardiologia D'Urgenza E Utic status: RECRUITING city: Roma state: RM zip: 00184 country: Italy name: VITTORIA RIZZELLO, MD role: CONTACT lat: 41.89193 lon: 12.51133 facility: Ospedale Isola Tiberina - Uoc Cardiologia Diagnostica Interventistica-Utic status: RECRUITING city: Roma state: RM zip: 00188 country: Italy name: MATTEO RUZZOLINI, MD role: CONTACT lat: 41.89193 lon: 12.51133 facility: Ospedale Sant'Andrea Di Roma - U.O.C. Cardiologia status: RECRUITING city: Roma state: RM zip: 00189 country: Italy name: EMANUELE BARBATO, MD role: CONTACT lat: 41.89193 lon: 12.51133 facility: Ospedale Santo Spirito - Uoc Cardiologia status: RECRUITING city: Roma state: RM zip: 00193 country: Italy name: ANGELA B SCARDOVI, MD role: CONTACT lat: 41.89193 lon: 12.51133 facility: Ospedale San Giovanni Evangelista - U.O.C. Di Cardiologia - Utic status: RECRUITING city: Tivoli state: RM zip: 00019 country: Italy name: ALFREDO POSTERARO, MD role: CONTACT lat: 41.95952 lon: 12.8016 facility: Ospedale Infermi - U.O. Cardiologia status: RECRUITING city: Rimini state: RN zip: 47900 country: Italy name: SAMUELA CARIGI, MD role: CONTACT lat: 44.05755 lon: 12.56528 facility: Ospedale Maria Ss. Addolorata - U.O. Di Cardiologia Utic status: RECRUITING city: Eboli state: SA zip: 84025 country: Italy name: ELISA DI IACONI, MD role: CONTACT lat: 40.61747 lon: 15.05693 facility: Aou S. Giovanni Di Dio-Ruggi D'Aragona - Cardiologia Intensiva Ospedaliera status: RECRUITING city: Salerno state: SA zip: 84131 country: Italy name: MICHELE R DI MURO, MD role: CONTACT lat: 40.67545 lon: 14.79328 facility: Aou S. Giovanni Di Dio-Ruggi D'Aragona - Ssd Utic status: RECRUITING city: Salerno state: SA zip: 84131 country: Italy name: AMELIA RAVERA, MD role: CONTACT lat: 40.67545 lon: 14.79328 facility: Ospedale San Luca - U.O. Utic - Cardiologia status: RECRUITING city: Vallo Della Lucania state: SA zip: 84078 country: Italy name: ANTONIO ALOIA, MD role: CONTACT lat: 40.22786 lon: 15.26635 facility: Ospedale Dell'Alta Val D'Elsa - Uosd Cardiologia-Utic status: RECRUITING city: Poggibonsi state: SI zip: 53036 country: Italy name: VALERIO ZACA', MD role: CONTACT lat: 43.47064 lon: 11.14804 facility: Aou Senese Ospedale S. Maria Alle Scotte - Cardiologia status: RECRUITING city: Siena state: SI zip: 53100 country: Italy name: SERAFINA VALENTE, MD role: CONTACT lat: 43.31822 lon: 11.33064 facility: Ospedale San Bartolomeo - Sc Riabilitazione Cardiologica status: RECRUITING city: Sarzana state: SP zip: 19038 country: Italy name: DANIELE BERTOLI, MD role: CONTACT lat: 44.11178 lon: 9.9622 facility: Ospedale E. Muscatello - U.O. Di Cardiologia - Utic status: RECRUITING city: Augusta state: SR zip: 96011 country: Italy name: GIOVANNI LICCIARDELLO, MD role: CONTACT lat: 37.24065 lon: 15.22121 facility: Ospedale G. Di Maria - Cardiologia Utic status: RECRUITING city: Avola state: SR zip: 96012 country: Italy name: PAOLO COSTA, MD role: CONTACT lat: 36.9084 lon: 15.13937 facility: Ospedale Ss. Annunziata - Cardiologia Clinica Ed Interventistica status: RECRUITING city: Sassari state: SS zip: 07100 country: Italy name: GAVINO CASU, MD role: CONTACT lat: 40.72586 lon: 8.55552 facility: Ospedale Nostra Signora Di Bonaria - U.O.C. Cardiologia E Utic status: RECRUITING city: San Gavino Monreale state: SU zip: 09037 country: Italy name: MARGHERITA CASULA, MD role: CONTACT lat: 39.55008 lon: 8.79065 facility: Po Ponente - Ospedale Santa Corona - Sc Cardiologia Ponente status: RECRUITING city: Pietra Ligure state: SV zip: 17027 country: Italy name: CHIARA BERNELLI, MD role: CONTACT lat: 44.1492 lon: 8.28206 facility: P.O. Levante - Ospedale San Paolo - S.C. Cardiologia Levante status: RECRUITING city: Savona state: SV zip: 17100 country: Italy name: ALBERTO SOMASCHINI, MD role: CONTACT lat: 44.30905 lon: 8.47715 facility: Casa Di Cura Villa Verde - Cardiologia status: RECRUITING city: Taranto state: TA zip: 74100 country: Italy name: ANGELO ALOISIO, MD role: CONTACT lat: 40.46435 lon: 17.24707 facility: Ospedale Santa Chiara - Divisione Di Cardiologia status: RECRUITING city: Trento state: TN zip: 38122 country: Italy name: MICHELE MORETTI, MD role: CONTACT lat: 46.06787 lon: 11.12108 facility: Ospedale Civico - Sc Cardiologia status: RECRUITING city: Chivasso state: TO zip: 10034 country: Italy name: CLAUDIO MORETTI, MD role: CONTACT lat: 45.19093 lon: 7.88981 facility: Por Cirié- Lanzo Presidio Cirié - S.C. Cardiologia status: RECRUITING city: Cirié state: TO zip: 10073 country: Italy name: MICHELE CAPRIOLO, MD role: CONTACT lat: 45.23486 lon: 7.60125 facility: Ospedale Civile - S.C. Cardiologia status: RECRUITING city: Ivrea state: TO zip: 10015 country: Italy name: MARCO M CINGOLANI, MD role: CONTACT lat: 45.46723 lon: 7.87617 facility: Aou San Luigi Gonzaga - S.C.D.O. Cardiologia status: RECRUITING city: Orbassano state: TO zip: 10043 country: Italy name: CARLOALBERTO BIOLÉ, MD role: CONTACT lat: 45.00547 lon: 7.53813 facility: Aou Citta' Della Salute E Della Scienza - S.C. Cardiologia U status: RECRUITING city: Torino state: TO zip: 10126 country: Italy name: Gaetano M De Ferrari, MD role: CONTACT lat: 45.07049 lon: 7.68682 facility: Ospedale Martini - Cardiologia (Mrt-Mv) status: RECRUITING city: Torino state: TO zip: 10142 country: Italy name: MASSIMO GIAMMARIA, MD role: CONTACT lat: 45.07049 lon: 7.68682 facility: Ospedale Maria Vittoria - Cardiologia (Mrt-Mv) status: ACTIVE_NOT_RECRUITING city: Torino state: To zip: 10149 country: Italy lat: 45.07049 lon: 7.68682 facility: Ospedale San Giovanni Bosco - Sc Cardiologia status: RECRUITING city: Torino state: TO zip: 10154 country: Italy name: PIERLUIGI SBARRA, MD role: CONTACT lat: 45.07049 lon: 7.68682 facility: Ospedale Santa Maria Del Carmine - Cardiologia status: RECRUITING city: Rovereto state: Trento zip: 38068 country: Italy name: ANNA MANICA, MD role: CONTACT lat: 45.8904 lon: 11.04053 facility: Asugi Trieste - Sc Patologie Cardiovascolari status: RECRUITING city: Trieste state: TS zip: 34125 country: Italy name: GIULIA RUSSO, MD role: CONTACT lat: 45.64953 lon: 13.77679 facility: Pou "Santa Maria Della Misericordia" - S.O.C. Cardiologia status: RECRUITING city: Udine state: UD zip: 33100 country: Italy name: MARZIA DE BIASIO, MD role: CONTACT lat: 46.0693 lon: 13.23715 facility: Ospedale Multimedica Castellanza - Cardiologia status: RECRUITING city: Castellanza state: VA zip: 21053 country: Italy name: LUCIA SAPORITI, MD role: CONTACT lat: 45.61079 lon: 8.89616 facility: Presidio Ospedaliero Di Saronno - U.O.C. Di Cardiologia status: RECRUITING city: Saronno state: VA zip: 21047 country: Italy name: DANIELE NASSIACOS, MD role: CONTACT lat: 45.62513 lon: 9.03517 facility: Ospedale Di Circolo Galmarini - Cardiologia status: RECRUITING city: Tradate state: VA zip: 21049 country: Italy name: PAOLA ANTOGNAZZA, MD role: CONTACT lat: 45.70843 lon: 8.90763 facility: Ospedale Sant'Andrea - Sc Cardiologia status: RECRUITING city: Vercelli state: VC zip: 13100 country: Italy name: ELISA RONDANO, MD role: CONTACT lat: 45.32163 lon: 8.41989 facility: Ospedale Dell'Angelo - U.O.C. Cardiologia status: RECRUITING city: Mestre state: VE zip: 30171 country: Italy name: SAKIS THEMISTOCLAKIS, MD role: CONTACT lat: 45.49167 lon: 12.24538 facility: Ospedale P.F. Calvi - Uos Di Cardiologia Riabilitativa status: RECRUITING city: Noale state: VE zip: 30033 country: Italy name: VALENTINA PESCATORE, MD role: CONTACT lat: 45.54596 lon: 12.06445 facility: Ospedale Civile - U.O.C. Di Cardiologia status: RECRUITING city: Arzignano state: VI zip: 36071 country: Italy name: CLAUDIO BILATO, MD role: CONTACT lat: 45.52027 lon: 11.33446 facility: Ospedale Alto Vicentino - U.O.C. Cardiologia - Ucic status: RECRUITING city: Santorso state: VI zip: 36014 country: Italy name: GIOVANNI MORANI, MD role: CONTACT lat: 45.73383 lon: 11.38785 facility: Ospedale G. Fracastoro - U.O.C. Di Cardiologia status: RECRUITING city: San Bonifacio state: VR zip: 37047 country: Italy name: MAURIZIO ANSELMI, MD role: CONTACT lat: 45.39595 lon: 11.27352 facility: Ospedale Civita Castellana - Ssd Cardiologia status: ACTIVE_NOT_RECRUITING city: Civita Castellana state: VT zip: 01033 country: Italy lat: 42.29304 lon: 12.40885 facility: Ospedale Belcolle - Uoc Cardiologia Ed Emodinamica status: RECRUITING city: Viterbo state: VT zip: 01100 country: Italy name: LUIGI SOMMARIVA, MD role: CONTACT lat: 42.41937 lon: 12.1056 facility: Ospedale Ss. Trinita' - S.C. Di Cardiologia status: RECRUITING city: Borgomanero zip: 28021 country: Italy name: PIERFRANCO S DELLAVESA, MD role: CONTACT lat: 45.69873 lon: 8.4623 facility: Istituti Clinici Scientifici Maugeri Irccs Sede Di Veruno - Uo Cardiologia Riabilitativa status: RECRUITING city: Gattico zip: 28013 country: Italy name: MASSIMO PISTONO, MD role: CONTACT lat: 45.70717 lon: 8.52003 facility: Ospedale Anna Rizzoli - Cardiologia-Utic status: ACTIVE_NOT_RECRUITING city: Lacco Ameno zip: 80076 country: Italy lat: 40.74901 lon: 13.88718 facility: Ospedale Buon Consiglio Fatebenefratelli - U.O.Complessa Di Cardiologia E Utic status: RECRUITING city: Napoli zip: 80123 country: Italy name: GAETANO M RUOCCO, MD role: CONTACT lat: 40.85216 lon: 14.26811 facility: Aorn Cardarelli - U.O. Cardiologia Con Utic status: RECRUITING city: Napoli zip: 80131 country: Italy name: CIRO MAURO, MD role: CONTACT lat: 40.85216 lon: 14.26811 facility: Aorn Ospedale Dei Colli - P.O. Monaldi - Uosd Card. Riabilitativa Intensiva E Scompenso status: RECRUITING city: Napoli zip: 80131 country: Italy name: GIUSEPPE PACILEO, MD role: CONTACT lat: 40.85216 lon: 14.26811 facility: Aorn Ospedale Dei Colli - P.O. Monaldi - Uosd Malattie Cardiologiche Congenite Adulti-Guch status: RECRUITING city: Napoli zip: 80131 country: Italy name: BERARDO SARUBBI, MD role: CONTACT lat: 40.85216 lon: 14.26811 facility: Ospedale S. Giovanni Bosco - Sc Cardiologia - Utic status: RECRUITING city: Napoli zip: 80134 country: Italy name: PAOLO TAMMARO, MD role: CONTACT lat: 40.85216 lon: 14.26811 facility: Aou Maggiore Della Carita' - Scdo Cardiologia Ii status: RECRUITING city: Novara zip: 28100 country: Italy name: LIDIA ROSSI, MD role: CONTACT lat: 45.44694 lon: 8.62118 facility: Ospedale Santa Maria Delle Grazie - U.O. Cardiologia - Utic Con Emodinamica status: RECRUITING city: Pozzuoli zip: 80078 country: Italy name: MARIANO AVERSA, MD role: CONTACT lat: 40.84394 lon: 14.0952 hasResults: False
<\|newrecord\|> nctId: NCT06279975 id: Req-2023-01275; am23Sutter2 briefTitle: Pupillometric Evaluation in Patients Declared Brain Dead - a Prospective Quality Control Study acronym: INSPECT overallStatus: RECRUITING date: 2023-12-18 date: 2029-12 date: 2030-12 date: 2024-02-28 date: 2024-02-28 name: University Hospital, Basel, Switzerland class: OTHER briefSummary: The aim of the study is to verify the reliability of the current purely clinical examination of the pupils (without the support of a pupillometer) in the context of clinically suspected brain death, compared to the results of a non-invasive, automated, and highly precise monocular pupillometric examination. conditions: Brain Death conditions: Adults studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 50 type: ESTIMATED name: non-invasive device-supported, automated pupillometry measure: Reliability of clinical examination of pupils in patients with suspected brain death sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Intensive care unit at the University Hospital Basel status: RECRUITING city: Basel state: Basel-Stadt zip: 4031 country: Switzerland name: Raoul Sutter, Prof. role: CONTACT phone: +41 61 328 7928 email: [email protected] name: Raoul Sutter, Prof. role: PRINCIPAL_INVESTIGATOR name: Pascale Grzonka, MD role: SUB_INVESTIGATOR lat: 47.55839 lon: 7.57327 facility: University Hospital Basel status: RECRUITING city: Basel country: Switzerland name: Raoul Sutter, Prof. role: CONTACT email: [email protected] name: Pascale Grzonka, MD role: CONTACT email: [email protected] lat: 47.55839 lon: 7.57327 hasResults: False
<\|newrecord\|> nctId: NCT06279962 id: 2000034620 briefTitle: Survey Experiment to Estimate Level of Mental Illness Stigma Based on Condition and Gender overallStatus: COMPLETED date: 2023-06-15 date: 2023-09-15 date: 2023-09-15 date: 2024-02-28 date: 2024-02-28 name: Yale University class: OTHER name: Empower Through Health briefSummary: This study aims to measure levels of mental illness stigma based on condition and gender of the participants and individual portrayed with mental illness. conditions: Mental Illness conditions: Stigma, Social studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 379 type: ACTUAL name: Survey questionnaire measure: Level of acceptance for the individual depicted in the vignette as measured by PERSONAL ACCEPTANCE SCALE measure: Level of acceptance for the individual depicted in the vignette as measured by BROAD ACCEPTANCE SCALE sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Empowerment to Heal - Uganda city: Iganga country: Uganda lat: 0.60917 lon: 33.46861 hasResults: False
<\|newrecord\|> nctId: NCT06279949 id: 2000036999 id: 1K01MH136929-01 type: OTHER domain: NIMH *ID not yet added briefTitle: Confidential Care and Adolescent HIV Testing overallStatus: NOT_YET_RECRUITING date: 2026-04 date: 2027-10 date: 2027-10 date: 2024-02-28 date: 2024-02-28 name: Yale University class: OTHER name: National Institute of Mental Health (NIMH) briefSummary: The purpose of this study is to assess the feasibility and acceptability of structural intervention components to increase adolescent HIV testing uptake by improving the implementation of confidential care as standard practice in pediatric primary care. conditions: Hiv studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: FACTORIAL primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 4 type: ESTIMATED name: Provider training name: Clinic protocols measure: Feasibility, defined as the extent to which structural intervention components to improve confidential care implementation can be successfully carried out in pediatric primary care settings measure: Acceptability, defined as the perception among pediatric primary care clinic leadership and providers that structural intervention components to improve confidential care implementation are agreeable or satisfactory measure: Change in HIV testing uptake measure: Reach, defined as the number of adolescent patients who receive confidential care measure: Adoption, defined as the proportion of pediatric primary care providers who have time alone with and/or provide confidentiality assurances to adolescent patients measure: Implementation, defined as pediatric primary care provider fidelity to confidential care provision measure: Maintenance, defined as the extent to which confidential care is provided and adolescent patients are screened for, accept, and receive results of HIV testing 6-months post-intervention sex: ALL minimumAge: 13 Years maximumAge: 17 Years stdAges: CHILD hasResults: False
<\|newrecord\|> nctId: NCT06279936 id: B3002021000171 briefTitle: Neurobiological Underpinnings of Neuropsychological Consequences in Long COVID acronym: Cov-N-Psy overallStatus: ACTIVE_NOT_RECRUITING date: 2021-11-01 date: 2023-12-31 date: 2024-12-31 date: 2024-02-28 date: 2024-02-28 name: Universiteit Antwerpen class: OTHER name: UZA Foundation briefSummary: Objectives:
To describe the standardized evaluation of the psychological and cognitive function of long COVID patients and their evolution, to compare immunological and HPA-axis related biomarkers between long COVID patients and healthy controls, to explore cross-sectional and longitudinal associations between immunological measures and long COVID symptoms.
Study design:
Cov-N-Psy is a longitudinal observational study. Three groups will be included from 2021 until 2023: long COVID patients with neuropsychological complaints (P), COVID-survivors without persistent complaints (Ca) and healthy volunteers without a history of COVID-19 (Cb). The total sample size is estimated on 130. Four visits are organized: at baseline, three, six and twelve months.
The study is organized in three work packages (WP). WP1 includes a blood withdrawal and psychometric questionnaires and is part of every visit. WP2 includes cortisol measurement in saliva and takes place on the baseline visit for every participant and on the third visit for patients. Finally, WP3 includes a neurocognitive assessment at baseline for patients and Ca controls and on the third visit for patients. conditions: Long COVID studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 130 type: ACTUAL name: Neuropsychological battery name: Surveys and symptom severity questionnaires name: Blood withdrawal name: Saliva swabs measure: Concentration of immunological and HPA-axis markers measure: Rate of psychopathological and neurocognitive function of long COVID patients with neuropsychiatric complaints measure: Cross-sectional and longitudinal association between long COVID NP symptoms (BDI, HDRS, STAI, ISI, KEDS, FSS, NP battery ...) and immunological and cortisol measures (CAR, cytokines, serology, WBC, CRP, mitochondrial markers, TRYCATS, ...) sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: SINAPS city: Duffel state: Antwerp zip: 2570 country: Belgium lat: 51.09554 lon: 4.50903 typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2022-10-01 uploadDate: 2024-02-08T04:56 filename: Prot_SAP_000.pdf size: 1140716 hasResults: False
<\|newrecord\|> nctId: NCT06279923 id: TXB2023023 briefTitle: CD19-BAFF CAR-T Cells Therapy for Patients With Autoimmune Diseases overallStatus: RECRUITING date: 2024-04-15 date: 2027-02-01 date: 2027-02-01 date: 2024-02-28 date: 2024-04-09 name: Zhejiang University class: OTHER name: Shanghai YaKe Biotechnology Ltd. briefSummary: Clinical Trial for the safety and efficacy of CD19-BAFF CAR-T cells therapy for Autoimmune Diseases. conditions: Autoimmune Diseases studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 45 type: ESTIMATED name: CD19-BAFF Targeted CAR T-cells measure: Dose-limiting toxicity (DLT) measure: Incidence of treatment-emergent adverse events (TEAEs) measure: Multiple Myeloma (MM), Overall response rate (ORR) measure: Progression-free survival (PFS) measure: Duration of remission,DOR sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The first affiliated hospital of medical college of zhejiang university status: RECRUITING city: Hangzhou state: Zhejiang zip: 310000 country: China name: He Huang, MD role: CONTACT phone: 86-13605714822 email: [email protected] name: Yongxian Hu, MD role: CONTACT phone: +8615957162012 email: [email protected] lat: 30.29365 lon: 120.16142 hasResults: False
<\|newrecord\|> nctId: NCT06279910 id: 2021 36 (EOm) briefTitle: Calcifediol in the Treatment of SARS-CoV-2 Disease (COVID-19). acronym: COVIDIOL overallStatus: RECRUITING date: 2024-02-21 date: 2024-03-21 date: 2024-04-25 date: 2024-02-28 date: 2024-02-28 name: Complejo Hospitalario Universitario de Albacete class: OTHER briefSummary: Descriptive, retrospective, observational, anonymous, study to evaluate the potential effect of incorporating calcifediol into the therapeutic protocol of patients hospitalized for COVID-19 on mortality and other outcome variables, such as admission to the Intensive Care Unit (ICU), to "Gerencia de Atención Integrada (GAI) de Albacete". "Complejo Hospitalario Universitario de Albacete". Albacete (Spain)", based on the files of the MXXI medical records, Information System of the Laboratory (ISL) and Pharmacy. conditions: SARS-CoV 2 Pneumonia studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: RETROSPECTIVE count: 275 type: ESTIMATED name: Calcifediol measure: Measure mortality by differentiating groups: calcifediol yes/no. measure: Measure the need for ICU admission by differentiating the groups calcifediol yes/no. measure: Measure mortality in relation to baseline 25(OH)D levels measure: To evaluate the effect of calcifediol treatment on mortality in patients with severe 25(OH)D deficiency measure: Measure the composite variable poor prognosis, (death and ICU) by differentiating the groups calcifediol yes/no sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Complejo Hospitalario Universitario de la Gerencia de Atención Integrada (GAI) de Albacete status: RECRUITING city: Albacete zip: 02008 country: Spain name: Jose A Blazquez, MD role: CONTACT phone: +34967597100 phoneExt: 37214 email: [email protected] name: Laura Navarro, MD role: CONTACT phone: +34967597460 email: [email protected] name: Javier Torres, PhD. role: SUB_INVESTIGATOR lat: 38.99424 lon: -1.85643 facility: Maimónides Biomedical Research Institute of Córdoba (IMIBIC). status: WITHDRAWN city: Cordoba zip: 14004 country: Spain lat: 37.89155 lon: -4.77275 hasResults: False
<\|newrecord\|> nctId: NCT06279897 id: 2023-068 briefTitle: LBNP Tolerance With Skin Warming After Exercise Cold Stress overallStatus: RECRUITING date: 2022-01-24 date: 2025-09-30 date: 2025-09-30 date: 2024-02-28 date: 2024-02-28 name: University of Colorado, Colorado Springs class: OTHER briefSummary: Assess the effect of skin rewarming during lower body negative pressure upon arterial blood pressure and tolerance to simulated blood loss after exercise in the cold. conditions: Blood Pressure conditions: Blood Loss studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Participants will complete trial 1 at the beginning of the study. Participants will then complete trials 2 through 5 in a random, counterbalanced order. primaryPurpose: BASIC_SCIENCE masking: NONE maskingDescription: Participants are blinded to the skin temperature control. count: 10 type: ESTIMATED name: Skin Surface Rewarming name: Skin Surface Warming name: Skin Surface Heating name: Skin Surface Cooling measure: Arterial blood pressure measure: Tolerance to simulated blood loss measure: Core temperature measure: Cutaneous Vascular Conductance sex: ALL minimumAge: 18 Years maximumAge: 40 Years stdAges: ADULT facility: University of Colorado Colorado Springs status: RECRUITING city: Colorado Springs state: Colorado zip: 80918 country: United States name: James Pearson, PhD role: CONTACT phone: 719-255-3806 email: [email protected] lat: 38.83388 lon: -104.82136 typeAbbrev: Prot_ICF hasProtocol: True hasSap: False hasIcf: True label: Study Protocol and Informed Consent Form date: 2023-01-03 uploadDate: 2024-02-22T15:33 filename: Prot_ICF_000.pdf size: 315418 hasResults: False
<\|newrecord\|> nctId: NCT06279884 id: 2023YFC2308802-03 briefTitle: A Cohort Study on the Pathogen Spectrum of Liver Transplant Recipients Complicated With Infection overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2026-11 date: 2026-11 date: 2024-02-28 date: 2024-03-04 name: Zhejiang University class: OTHER name: Beijing Ditan Hospital name: Beijing YouAn Hospital name: Huashan Hospital name: Qilu Hospital of Shandong University briefSummary: The goal of this observational study is to map the pathogen profile of secondary infections in liver transplant recipients, to correlate the basic immune status with the characteristics of the secondary infection pathogen profile, and to establish an early warning system for monitoring secondary infections, so as to explore safe and effective therapeutic modalities to further reduce the morbidity and mortality of liver failure. The main questions it aims to answer are:
* Characterize the distribution of pathogenic bacteria infecting liver transplant recipients.
* Establish a monitoring and early warning system for secondary infections. conditions: Liver Transplantation conditions: Transplant Recipients studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 1000 type: ESTIMATED measure: Secondary Infections in liver transplant recipients at 4 weeks measure: quick SEPSIS RELATED ORGAN FAILURE ASSESSMENT(qSOFA) at 4 weeks measure: Occurrence of secondary infections in liver transplant recipients at 8 weeks, including site of infection, pathogen of infection measure: Occurrence of secondary infections in liver transplant recipients at 12 weeks, including site of infection, pathogen of infection measure: qSOFA score at 8 weeks measure: qSOFA score at 12 weeks sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<\|newrecord\|> nctId: NCT06279871 id: ARCT-2303-01 briefTitle: Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2024-10 date: 2024-12 date: 2024-02-28 date: 2024-02-28 name: Arcturus Therapeutics, Inc. class: INDUSTRY name: Seqirus name: Novotech (Australia) Pty Limited briefSummary: This is a multicenter, observer-blind, randomized, controlled phase 3 study to evaluate the immunogenicity, reactogenicity, and safety of an investigational self-amplifying RNA COVID-19 vaccine (ARCT-2303) administered concomitantly with quadrivalent influenza vaccines or standalone in adults who previously received authorized COVID-19 vaccine. conditions: COVID-19 studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 1680 type: ESTIMATED name: ARCT-2303 name: Influenza vaccine name: Influenza vaccine, adjuvanted name: Placebo measure: SARS-CoV-2 neutralizing antibody titers measure: SARS-CoV-2 neutralizing antibody seroconversion rates measure: Hemagglutination Inhibition (HI) titers measure: SARS-CoV-2 neutralizing antibody titers measure: SARS-CoV-2 neutralizing antibody titers measure: SARS-CoV-2 neutralizing antibody seroconversion rates measure: SARS-CoV-2 neutralizing antibody response (Group 1a; Group 2a) measure: Hemagglutination Inhibition (HI) titers measure: SARS-CoV-2 neutralizing antibody responses measure: Hemagglutination Inhibition (HI) assay titers measure: Local and systemic adverse events (AEs) measure: Unsolicited AEs measure: SAE, Medically Attended Adverse Events (MAAE), Adverse Events of Special Interest (AESI), and AE leading to early termination sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<\|newrecord\|> nctId: NCT06279858 id: 1-2024 briefTitle: Probiotic Intervention for Microbiome Modifications and Clinical Improvements in Fragile X Syndrome overallStatus: RECRUITING date: 2024-01-01 date: 2024-12-31 date: 2024-12-31 date: 2024-02-28 date: 2024-02-28 name: Specila hospital for cerebral palsy and developmental neurology class: OTHER name: FRAXA Research Foundation briefSummary: The primary objective of this clinical trial is to evaluate efficacy of probiotic mixture which contains Lactobacillus casei, Lactobacillus salivarius and Bifidobacterium breve, in children with Fragile X aged 3-18 years. Specifically, links between microbiome modifications by probiotic mixture and behavioral manifestations and brain processing (eye tracker, EEG analysis) will be assessed. Exploratory objects of this trial are analyses of microbiome composition and assessment of its alterations and modifications (by probiotic mixture) that may lead to clinical improvement and prediction which patients with FXS may be likely to benefit from probiotics treatment.
This is open label trial without masking, where each participant receives probiotic for 3 months (12 weeks). It will be single group assignment. The study plans to enroll 15 participants with FXS, aged 3-18 years, both sexes, during 1-year period and complete all study-related activities by January 2025. During the 3-month study period, subjects will attend three visits (screening/baseline, 6-week, and 3-month visits) to the Fragile X Clinic at the Special Hospital for Cerebral Palsy and Developmental Neurology, Belgrade, Serbia. The primary outcome measureswill be Vineland Adaptive Behavior Scales-Third Edition (VABS-III) and eye tracking measures (social gaze and pupillometry). Exploratory endpoint will be microbiome analyses. Secondary outcome measures will be: CGI-S and CGI-I scores, ABC-CFX score, quality of life, sleep habits and EEG analyses. conditions: Fragile X Syndrome studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: This is open label trial without masking, where each participant receives probiotic for 3 months (12 weeks). It will be single group assignment. In this approach, participants act as their own controls by measuring the microbiome and other parameters before and after taking the probiotics. This design was chosen because individual's microbiome is highly personalized. Even within a family, individuals can have distinct microbiomes. The unique composition of an individual's microbiome can have implications for the effectiveness of probiotics. Thus, changes in analyses and scores between baseline and 3-month study period will be assessed for everyone. Specifically, microbiome modifications that may be associated with changes in behavior and brain processing will be examined. primaryPurpose: BASIC_SCIENCE masking: NONE count: 15 type: ESTIMATED name: Probiotics measure: 1. Vineland Adaptive Behavior Scales-Third Edition (VABS-III) measure: Eye tracking measure: Clinical Global Impression Scales of Severity (CGI-S) and Improvement (CGI-I) - measure: The Aberrant Behavior Checklist - Community Edition (ABC-C), scored using the FXS-specific factoring system (ABC-CFX) measure: Pediatric Quality of Life Questionnaire (PedsQL) Parent Proxy measure: Child Sleep Habits Questionnaire (CSHQ) measure: EEG analyses measure: Microbiome analyses sex: ALL minimumAge: 3 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: Special Hospital for Cerebral Palsy and Developmental Neurology status: RECRUITING city: Belgrade zip: 11000 country: Serbia name: Dragana Protic, Prof. role: CONTACT phone: +381640667466 email: [email protected] name: Sanja Dimitrijevic, PhD role: CONTACT phone: +381640667466 email: [email protected] lat: 44.80401 lon: 20.46513 hasResults: False
<\|newrecord\|> nctId: NCT06279845 id: 2023YFC2308802-02 briefTitle: A Clinical Cohort Study on the Pathogen Spectrum of Hepatic Virus-caused Cirrhosis Complicated With Infection overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2026-11 date: 2026-11 date: 2024-02-28 date: 2024-03-04 name: Zhejiang University class: OTHER name: Beijing Ditan Hospital name: Beijing YouAn Hospital name: Huashan Hospital name: Qilu Hospital of Shandong University briefSummary: The goal of this observational study is to expound the population and characteristics of pathogenic microorganisms with co-infection, draw the pedigree of pathogenic microorganisms, and evaluate its influence on disease outcome in patients with hepatic virus-caused cirrhosis. The main questions it aims to answer are:
* Describe the populations and characteristics of pathogenic microorganisms responsible for co-infections in patients with hepatic virus-caused cirrhosis.
* Map the spectrum of pathogenic microorganisms, and evaluate their impact on disease regression. conditions: Liver Cirrhosis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 2000 type: ESTIMATED measure: Secondary infection in patients at 4 weeks measure: quick SEPSIS RELATED ORGAN FAILURE ASSESSMENT(qSOFA) at 4 weeks measure: Survival rate sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<\|newrecord\|> nctId: NCT06279832 id: 3994 briefTitle: Radiomics and Radiogenomics Models to Predict Molecular Integrated Risk Classes and Prognostic Factors in Endometrial Cancer. acronym: Romantic overallStatus: RECRUITING date: 2023-11-01 date: 2024-10-31 date: 2025-10-31 date: 2024-02-28 date: 2024-02-28 name: Fondazione Policlinico Universitario Agostino Gemelli IRCCS class: OTHER briefSummary: The aim is to develop radiogenomics models to stratify patients into three main risk categories (Favorable, Intermediate, and Unfavorable) according to the ProMisE model (9) and use these models to predict the most prognostically relevant EC histopathological features (i.e. FIGO stage, degree of tumor differentiation, histotype, LVSI status, myometrial and cervical invasion, lymph node metastases).
These models would support clinicians in personalizing surgical and adjuvant treatment choice among the options considered by the international guidelines. conditions: Endometrial Cancer studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: As far as the sample size concerns, the number of images required for the analysis are a figure of at least 100 positive cases (15). We considered as positive patients with a favorable prognostic profile according to PORTEC-4a and also low and intermediate risk class according to ESGO/ESTRO/ESP 2020 recommendations.Therefore, we estimate to enroll at least 1000 patients in order to reach the 100 positive cases. primaryPurpose: DIAGNOSTIC masking: NONE count: 1000 type: ESTIMATED name: trascriptomic profiling measure: Predictive value of the model measure: Validity of the model sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fondazione Policlinico Agostino Gemelli IRCSS status: RECRUITING city: Rome state: Lazio zip: 00118 country: Italy name: francesco fanfani role: CONTACT phone: 0630151 email: [email protected] lat: 41.89193 lon: 12.51133 hasResults: False
<\|newrecord\|> nctId: NCT06279819 id: 2024-008 briefTitle: Effectiveness of Gut Microbiota-targeted Dietary Intervention Among HIV-infected Patients overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2024-12-31 date: 2024-12-31 date: 2024-02-28 date: 2024-02-28 name: Fudan University class: OTHER briefSummary: The goal of this clinical trial is to conduct a dietary intervention targeting HIV-specific gut microbiota alterations for primary ASCVD prevention and evaluate its effectiveness in preventing borderline ASCVD risk among HIV-infected patients. The main questions it aims to answer are:
* Explore the pivotal role of the gut-heart axis in the causal relationship between HIV infection and atherosclerotic cardiovascular disease.
* Develop a targeted dietary intervention focusing on gut microbiota to prevent the borderline risk of atherosclerotic cardiovascular disease in HIV-infected patients.
* Evaluate the effectiveness of the gut microbiota-targeted dietary intervention in reducing atherosclerotic cardiovascular disease risk among HIV-infected patients, altering gut microbiota composition, improving risk factors of atherosclerotic cardiovascular disease, and alleviating prodromal symptoms associated with atherosclerotic cardiovascular disease.
Participants in the intervention group will receive the gut microbiota-targeted dietary intervention thrice weekly for 3 months, accompanied by bi-weekly health education videos for the same duration. Meanwhile, the control group will continue routine follow-up and health education practices. The intervention will span three months, followed by a three-month follow-up period. Data collection will occur at baseline, 3 months, and 6 months. conditions: Hiv conditions: Cardiovascular Diseases conditions: Diet, Healthy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 106 type: ESTIMATED name: gut microbiota-targeted dietary intervention measure: ASCVD risk estimated by the PCE measure: The composition of gut microbiota measure: fasting blood lipids measure: blood pressure measure: BMI measure: ASCVD symptoms sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fudan University city: Shanghai state: Shanghai zip: 200032 country: China name: Junwen Yu role: CONTACT phone: 13320178333 email: [email protected] lat: 31.22222 lon: 121.45806 hasResults: False
<\|newrecord\|> nctId: NCT06279806 id: SerapAlkas briefTitle: The Effect of Mobile Health Application on Posttraumatic Growth in Women Diagnosed With Breast Cancer overallStatus: NOT_YET_RECRUITING date: 2024-02-28 date: 2024-06-30 date: 2024-10-30 date: 2024-02-28 date: 2024-02-28 name: Gazi University class: OTHER briefSummary: Breast cancer is the type of cancer that significantly affects women's health and causes the most mortal in women. Despite the high incidence of breast cancer, women living after breast cancer are increasing due to advances in early diagnosis and effective treatment options. Treatments are aimed at prolonging survival from breast cancer and enabling patients to live better. Women repeatedly experience many vital crises such as the diagnosis of cancer, the difficulties of the treatment process and the fear of recurrence in the post-treatment period. In the face of these crises, post-traumatic growth occurs when the individual's efforts to cope are transformed into positive psychological experiences. Positive experiences lead to improvement in women's life, while negative experiences make it difficult to cope and adapt. In order for post-traumatic growth to take place, women should be supported to cope with these negative emotions. The care given to patients during cancer treatment should be such as to support the change process that will help individuals adapt to the new lifestyle.This information and supportive care content should include the topics that women will need in the long term after the treatment, in addition to the diagnosis and treatment process. Generally, the education and counseling given to the patient at the last treatment appointment may be limited. Due to the long period from the last treatment appointment to the control appointment, patients cannot interact with healthcare professionals for a long time. Long-term side effects and needs of people may differ after breast cancer treatment. For this reason, the need for information and consultancy services of healthcare professionals continues in this process as well.Today, the use of remotely accessible mechanisms in the treatment of breast cancer and in the follow-up of women after treatment is increasing. It is thought that the mobile application to be developed within the scope of the project will increase the quality and efficiency of health services with an R\&D and innovative approach and make these services accessible to everyone through digital technologies. In addition, our study will set an example for nursing care to be presented in one of the priority areas of health, such as cancer, through digital technologies. In our study, it is aimed to evaluate the effect of mobile health application based on Mezirow's Transformational Learning Theory on post-traumatic development in women with breast cancer. The research is a single center, parallel group, stratified block randomized controlled experimental study. It is planned to be conducted with 56 (intervention: 28, control: 28) women at Gazi University Health Research and Practice Center. The training content to be included in the mobile application has been determined by considering the results of the studies in the literature and the recommendations of international guides to determine the problems experienced by women with breast cancer during the post-treatment period. After receiving expert opinions on the subject content, the development process of the mobile application will be started. In the implementation phase of the study, the women in the intervention group will start using the mobile application 1 week after completing the active treatment chemotherapy and radiotherapy) process.The implementation of the study will last 8 weeks. At the end of eight weeks, data collection tools will be applied to the women. The final tests will be repeated 4 weeks after the end of the application. Starting from this period, women in the control group who want to use the application will also be included in the mobile application system. After completing the data collection tools, the analysis and reporting part will be started. Statistical analyzes will be made using SPSS Package Program (IBM SPSS Statistics 27). Student t test, Pearson Chi-square test, Independent Sample t test, Mann Whitney U test, One-Way Analysis of Variance or Friedman test will be used in the analyses. conditions: Posttraumatic Growth conditions: Grief studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: In order to ensure similarity between the groups, stratified block randomization will be used to assign the women in the sample group to the experimental and control groups. In this method, after stratification according to risk factors, block randomization is performed within each stratum. Since the type of treatment applied in breast cancer and marital status will significantly affect posttraumatic development, stratification was made in terms of these parameters. Stratum 1 in terms of treatment type: Mastectomy, 2nd stratum: Breast conserving surgery or reconstructive surgery during mastectomy; Stratum 1 in terms of partner presence: Has a partner, Stratum 2: No partner. In order to determine which stratum group the women who were found to meet the research criteria and who agreed to participate in the study were in, blocks will be formed with a combination of 4 and the assignment list will be determined through the www.randomizer.org website. primaryPurpose: SUPPORTIVE_CARE masking: SINGLE maskingDescription: The data obtained from the research will be coded as A and B by an independent researcher and transferred to the SPSS program. The data will also be analyzed by an independent statistician. whoMasked: OUTCOMES_ASSESSOR count: 56 type: ESTIMATED name: Mobile health application use name: Information of the breast cancer survivor period booklet measure: Women's progression through the stages of grief measure: Women's increased level of posttraumatic development sex: FEMALE stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<\|newrecord\|> nctId: NCT06279793 id: MODIFYCSX briefTitle: Intravenous Fish Oil Based Lipid Emulsion to Enhance Recovery in High-Risk Cardiac Surgery Patients. acronym: MODIFYCSX overallStatus: RECRUITING date: 2024-02-15 date: 2024-12-01 date: 2025-12-01 date: 2024-02-28 date: 2024-02-28 name: GCP-Service International West GmbH class: INDUSTRY name: Charite University, Berlin, Germany name: Wuerzburg University Hospital briefSummary: The proposing study is a randomized, double-blind, controlled trial of about 120 patients in 10 centers in Germany. This trial will be started in Germany and recruited mainly at powerful German heart centers only.
In this prospective randomized controlled blinded multicenter trial, a total of 120 high-risk cardiac surgery patients will receive either standard of care + OMEGAVEN at 0.20 g/kg ideal body weight (IBW) versus placebo + standard of care. conditions: Cardiac Surgery conditions: High Risk Patients conditions: Intensive Care Unit conditions: Cardiopulmonary Bypass conditions: Valve Surgeries studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomization will be stratified by site, employing a web-based system using a 1:1 ratio to either intravenous FO- based lipid emulsion (Omegaven®), or placebo. primaryPurpose: TREATMENT masking: QUADRUPLE maskingDescription: Researchers and clinical staff will be blinded to study intervention allocation. Unblinded delegate at each site will be able to prepare and dispense the investigational drug or placebo. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 120 type: ESTIMATED name: Long-chain n-3 fatty acids name: Intravenous 0.9% Sodium Chloride measure: Atrial fibrillation measure: Weaning from cardiopulmonary bypass (CPB) measure: Time to discharge alive measure: Persistent Organ Dysfunction + Death measure: Days alive and out of hospital measure: Hospital length of stay measure: ICU length of stay measure: Simplified Acute Physiology Score measure: Therapeutic Intervention Scoring System measure: ICU and Hospital Readmission rates measure: Delta Sequential Organ Failure Assessment Score (SOFA) Score measure: Mechanical ventilation measure: Stroke measure: Acute Kidney Injury measure: Infections rate measure: Clinical frailty scale measure: Development of delirium measure: Survival status measure: Physical activity assessment measure: Quality of Life (SF-36) measure: Adverse Events measure: Postoperative bleeding measure: Optional-Ultrasound measurement measure: Optional-Functional Status Score for Intensive Care Unit measure: Optional-Short Physical Performance Battery test measure: Optional-Hand grip dynamometer measure: Optional-Hand held dynamometer measure: Optional-Manual Muscle Testing measure: Optional-Left ventricular ejection function measure: Optional-Markers of inflammation measure: Optional-Hemodynamics measure: Sub-study sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: RWTH Aachen University status: NOT_YET_RECRUITING city: Aachen country: Germany name: Moritz Immohr, M.D role: CONTACT email: [email protected] name: Aileen Hill, M.D role: CONTACT email: [email protected] lat: 50.77664 lon: 6.08342 facility: Charité Universitätsmedizin Berlin status: NOT_YET_RECRUITING city: Berlin country: Germany name: Sascha Ott, M.D role: CONTACT email: [email protected] name: Maren Kleine-Brüggeney, M.D role: CONTACT email: [email protected] lat: 52.52437 lon: 13.41053 facility: University of Bonn status: NOT_YET_RECRUITING city: Bonn country: Germany name: Markus Velten, M.D role: CONTACT email: [email protected] name: Maria Wittmann, M.D role: CONTACT email: [email protected] lat: 50.73438 lon: 7.09549 facility: Universität Göttingen status: NOT_YET_RECRUITING city: Göttingen country: Germany name: Reiner Wäschle, M.D role: CONTACT email: [email protected] name: Anselm Bräuer, M.D. role: CONTACT email: [email protected] lat: 51.53443 lon: 9.93228 facility: University Medical Center Schleswig-Holstein status: NOT_YET_RECRUITING city: Kiel country: Germany name: Elke Gunnar, M.D role: CONTACT email: [email protected] name: Matthias Lindner, M.D role: CONTACT email: [email protected] lat: 54.32133 lon: 10.13489 facility: University of Muenster status: RECRUITING city: Münster country: Germany name: Alexander Zarbock, M.D role: CONTACT email: [email protected] name: Carola Wempe, M.D role: CONTACT email: [email protected] lat: 51.96236 lon: 7.62571 hasResults: False
<\|newrecord\|> nctId: NCT06279780 id: PI18/00932 briefTitle: Gut Microbiota, Mitochondrial Function and Metabolic Health in Obesity overallStatus: ACTIVE_NOT_RECRUITING date: 2019-01-01 date: 2023-12-31 date: 2024-08-31 date: 2024-02-28 date: 2024-02-28 name: Celia Bañuls class: OTHER name: Instituto de Salud Carlos III briefSummary: It has been suggested that individuals with the condition known as metabolically healthy obesity (MHO) may not have the same increased risk of developing metabolic abnormalities as their non-metabolically healthy counterparts. In addition, to date, the identification of metabolic biomarkers and microbiota underlying the MHO state is limited. In this study, our goal is to provide insight into the underlying metabolic pathways affected by obesity. To achieve this, we will compare the metabolic profile, inflammatory parameters and mitochondrial function, as well as metabolomic analysis and differential expression of microbiota in obese patients categorized as metabolically healthy vs. non healthy. In parallel, the effect of a hypocaloric diet on obese subjects' metabolism and microbiota will be assessed to approve their use in the treatment of said disorder. Specifically, we propose an observational, clinical-basic, comparative and interventional study in a population of 80 obese (BMI\>35 kg/m2) patients clustered in two groups according to the presence or absence of altered metabolism (altered fasting glycemia, hypertension, atherogenic dyslipidemia). Anthropometric and clinical variables and biological samples (serum, plasma, peripheral blood cells and feces) will be collected for the determination of biochemical parameters (glucose, lipid and hormonal profile by enzymatic techniques) and protein-based peripheral biomarkers of mitochondrial function \[total and mitochondrial reactive oxygen species (ROS) production, mitochondrial membrane potential, glutathione levels by static cytometry\], markers of mitochondrial dynamics \[Mitofusin 1 (MFN1), Mitofusin 2 (MFN2), Mitochondrial fision protein 1 (FIS1) and Dynamin-related protein 1 (DRP1) by RT-PCR and Western Blot\], markers of inflammation \[Interleukin 6 (IL6), Tumoral necrosis factor alpha (TNFα), IL1b, adiponectin, resistin, plasminogen activator inhibitor 1 (PAI-1), Monocyte chemoattractant protein-1 (MCP-1), caspase 1 and NLRP3 by Western Blot and technology XMAP), metabolomic assay (NMR spectroscopy and PLS-DA), as well as gut microbiota content and diversity (16S rRNA, MiSeq sequencing). Finally, we will evaluate the effect of a dietary weight loss intervention on these biomarkers. conditions: Obesity Adult Onset studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 109 type: ACTUAL name: very low-calorie diet measure: Analyze the changes in the diversity of the intestinal microbiota after dietetic intervention. measure: Evaluate the differences in the diversity of the intestinal microbiota depending on whether patients present metabolically healthy obesity (MHO) or metabolically unhealthy obesity (MUHO). measure: Evaluate significant changes in body fat mass percentage after the dietetic intervention. measure: Assess significant changes in high-sensitivity C-reactive protein (hs-CRP) as an inflammatory parameter after the dietetic intervention. measure: Evaluate significant changes in C3 protein as an inflammatory parameter after the dietetic intervention. measure: Assess significant changes in plasmatic homocysteine as an inflammatory parameter after the dietetic intervention. measure: Evaluate significant changes in interleukin 1-beta (IL-1B) levels as a pro-inflammatory molecule after the dietetic intervention. measure: Evaluate significant changes in interleukin 6 (IL-6) levels as a pro-inflammatory molecule after the dietetic intervention. measure: Evaluate significant changes in tumor necrosis factor alpha (TNF-alpha) levels as a pro-inflammatory molecule after the dietetic intervention. measure: Assess significant changes in superoxide dismutase (SOD) levels after the dietetic intervention. measure: Analyze the significant differences between metabolomic profile before and after the dietetic intervention. measure: Evaluate if there is a significant reduction after the dietetic intervention in total ROS levels. measure: Assess if there is a significant reduction after the dietetic intervention in glutathione levels. measure: Analyze if there is a significant change after the dietetic intervention in total free radicals and superoxide levels. measure: Analyze if there is a significant reduction after the dietetic intervention in mitochondrial ROS production. measure: Evaluate if there is a significant improvement after the dietetic intervention in mitochondrial membrane potential. measure: Analyze the proportion of subjects achieving at least 10% reduction in weight compared with baseline. sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: FISABIO city: Valencia zip: 46020 country: Spain lat: 39.46975 lon: -0.37739 hasResults: False
<\|newrecord\|> nctId: NCT06279767 id: 2022-SR-557 briefTitle: Efficacy and Safety of TMZ Plus 6-MP in the Patients With Recurrent Glioblastoma overallStatus: RECRUITING date: 2022-07-01 date: 2025-07-01 date: 2025-07-31 date: 2024-02-28 date: 2024-02-28 name: The First Affiliated Hospital with Nanjing Medical University class: OTHER briefSummary: Glioblastoma, the most prevalent malignant tumor in the central nervous system, is characterized by high invasiveness and a propensity to recur, contributing to a relatively elevated mortality rate. Patients diagnosed with high-grade glioblastomas typically experience a median survival period of less than 14 months. Presently, the standard treatment for glioblastoma involves surgical resection combined with postoperative radiotherapy and chemotherapy, with postoperative chemotherapy playing a pivotal role in enhancing patient prognosis. Temozolomide (TMZ), a cutting-edge oral alkylating agent known for its advantageous properties, including easy traversal of the blood-brain barrier, induces DNA alkylation in tumor cells, fostering apoptosis. Currently, it serves as a frontline medication for postoperative chemotherapy in glioblastoma. However, clinical resistance to TMZ chemotherapy significantly hampers its efficacy in later stages. We have recently discovered and validated that 5-aminoimidazole-4-carboxamide (AICA), derived from TMZ, can transform into 5-aminoimidazole-4-carboxamide ribonucleotide-5-phosphate (AICAR) in GBM cells. Hypoxanthine phosphoribosyltransferase 1 (HPRT1) has been identified as the catalyst for the AICA reaction, generating AICAR. AICAR acts as an endogenous activator of AMP-activated protein kinase (AMPK), fostering chemoresistance in glioblastoma through the activation of the AMPK signaling pathway. 6-mercaptopurine (6-MP) competes effectively to inhibit HPRT1 activity, thereby impeding TMZ-induced AMPK activation and significantly heightening glioblastoma cell sensitivity to TMZ. In this project, we propose an innovative strategy involving the combination of 6-MP with TMZ for the treatment of glioblastoma. conditions: Glioblastoma conditions: Cancer conditions: Temozolomide studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 27 type: ESTIMATED name: 6-mercaptopurine measure: PFS measure: OS measure: Safety evaluation sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Neurosurgery of The First Affiliated Hospital of Nanjing Medical University status: RECRUITING city: Nanjing state: Jiangsu zip: 210029 country: China name: Yongping You, PhD role: CONTACT phone: 13770694258 email: [email protected] lat: 32.06167 lon: 118.77778 hasResults: False
<\|newrecord\|> nctId: NCT06279754 id: ZLXGBXKYXM-031-01 briefTitle: Recombinant Human Endostatin Combined With Envafolimab and Synchronal Radiochemotherapy overallStatus: NOT_YET_RECRUITING date: 2024-02-18 date: 2024-06-18 date: 2025-12-18 date: 2024-02-28 date: 2024-02-28 name: The First Affiliated Hospital of Xinxiang Medical College class: OTHER briefSummary: This study is a prospective, single arm, single center open clinical study aimed at evaluating the efficacy and safety of recombinant human endostatin and envafolimab combined with synchronal radiochemotherapy in patients with locally advanced squamous non-small cell lung cancer who cannot undergo surgery in stage III. conditions: Locally Advanced Squamous Non-small Cell Lung Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: Recombinant Human Endostatin Injection measure: objective response rate measure: Overall survival measure: Progression-free survival sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<\|newrecord\|> nctId: NCT06279741 id: EVENEW id: 2022-500293-34 type: EUDRACT_NUMBER id: U1111-1291-0283 type: OTHER domain: Universal Trial Number briefTitle: Safety and Efficacy of MSC-EVs in the Prevention of BPD in Extremely Preterm Infants acronym: EVENEW overallStatus: RECRUITING date: 2023-12-28 date: 2027-01-31 date: 2029-12-31 date: 2024-02-28 date: 2024-02-28 name: EXO Biologics S.A. class: INDUSTRY briefSummary: The phase 1/2 trial aims to evaluate the safety and efficacy of EXOB-001 consisting of extracellular vesicles derived from umbilical cord mesenchymal stromal cells in the prevention of bronchopulmonary dysplasia (BPD) in extremely premature neonates. The study population includes babies born between 23 and 28 (27 + 6 days) weeks of gestational age and body weight between 500g and 1,500 g. Thirty-six subjects will receive one or three administrations of the three doses of EXOB-001 via the endotracheal route in phase 1. In phase 2, two dosages based on the results of phase 1 will be selected and a total of 203 subjects will be randomised to receive either EXOB-001 or placebo (saline solution).
Infants will be followed up to 2 years of corrected age (end of study). conditions: Bronchopulmonary Dysplasia studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Phase 1 is an open-labelled, dose-escalated, and single-arm of EXOB-001. Phase 2 is a randomised, double-blind, placebo-controlled, and dose-finding of EXOB-001. primaryPurpose: PREVENTION masking: DOUBLE maskingDescription: Phase 1 is an open-label, dose-escalation and single-arm study. In phase 2, Investigators will remain blinded to each subject's assigned treatment throughout the study. The Sponsor will put in place procedures to maintain this blind. Indeed, to ensure the blinding of the groups, the preparation and administration of the test product will be organized by different teams. In the event of a Quality Assurance audit, the auditor(s) will be allowed access to unblinded study treatment records at the site(s) to verify that randomisation/dispensing has been done accurately. Blinding will be broken by the Investigator for emergency purposes only, where knowledge of the blinded treatment could influence further subject care. In addition, subjects will be unblinded for safety reports, as per regulatory requirements. Study blind will be broken after the database lock. whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 265 type: ESTIMATED name: Endotracheopulmonary Instillation, Suspension measure: Number of subjects with treatment-emergent adverse events (phase 1) measure: Number of subjects with BPD grade II-III incidence rate per groups (phase 2). measure: Assessment of medium-term safety of EXOB-001 (phase 1/2) measure: Number of subjects with dose-limiting toxicity (DLT) (phase 1) measure: Number of subjects needing for oxygen and ventilation for BPD incidence (phase 1/2) measure: Assessment of immune markers (phase 2) measure: Assessment of BPD incidence and severity (phase 1/2) measure: Safety evaluation (phase 1/2) measure: Assessment of lung ultrasound score (phase 1/2) measure: Number of subjects with complications of prematurity (phase 1/2) measure: Assessment of the respiratory morbidity (phase 1/2) measure: Assessment of neurodevelopment (phase 1/2) sex: ALL maximumAge: 10 Days stdAges: CHILD facility: Cliniques Universitaires Saint-Luc (UCLouvain) status: NOT_YET_RECRUITING city: Brussels zip: 1200 country: Belgium name: Olivier Danhaive, M.D. role: CONTACT phone: +32 2 764 79 00 email: [email protected] name: Olivier Danhaive, M.D. role: PRINCIPAL_INVESTIGATOR lat: 50.85045 lon: 4.34878 facility: ISPPC CHU Charleroi status: NOT_YET_RECRUITING city: Charleroi zip: 6000 country: Belgium name: Serge Vanden Eijnden, M.D. role: CONTACT phone: +32 7 192 12 43 email: [email protected] name: Serge Vanden Eijnden, M.D. role: PRINCIPAL_INVESTIGATOR lat: 50.41136 lon: 4.44448 facility: Clinique CHC Montlégia status: NOT_YET_RECRUITING city: Liège zip: 4000 country: Belgium name: Pierre Maton, M.D. role: CONTACT phone: +32 4 355 56 17 email: [email protected] name: Pierre Maton, M.D. role: PRINCIPAL_INVESTIGATOR lat: 50.63373 lon: 5.56749 facility: AOU Careggi status: NOT_YET_RECRUITING city: Florence country: Italy name: Carlo Dani, M.D. role: CONTACT phone: +39 055 7948421 email: [email protected] name: Carlo Dani, M.D. role: PRINCIPAL_INVESTIGATOR lat: 43.77925 lon: 11.24626 facility: IRCCS Instituto Giannina Gaslini status: NOT_YET_RECRUITING city: Genova country: Italy name: Giorgia Brigati, M.D. role: CONTACT phone: +39 010 56362218 email: [email protected] name: Giorgia Brigati, M.D. role: PRINCIPAL_INVESTIGATOR lat: 44.40478 lon: 8.94438 facility: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico status: NOT_YET_RECRUITING city: Milan country: Italy name: Anna Lavizzari, M.D. role: CONTACT email: [email protected] role: CONTACT phone: +39 025 5032907 name: Anna Lavizzari, M.D. role: PRINCIPAL_INVESTIGATOR lat: 45.46427 lon: 9.18951 facility: AOU Policlinico di Modena status: NOT_YET_RECRUITING city: Modena country: Italy name: Alberto Berardi, M.D. role: CONTACT phone: +39 333 1053301 email: [email protected] name: Alberto Berardi, M.D. role: PRINCIPAL_INVESTIGATOR lat: 44.64783 lon: 10.92539 facility: Unità di Fase I della UOC Terapia Intensiva e Patologia Neonatale, Assistenza Neonatale (TINI) dell'Azienda Ospedale Università di Padova status: RECRUITING city: Padua zip: 35128 country: Italy name: Eugenio Baraldi, Prof role: CONTACT phone: +39 049 8213578 email: [email protected] name: Eugenio Baraldi, Prof role: PRINCIPAL_INVESTIGATOR lat: 45.40797 lon: 11.88586 hasResults: False
<\|newrecord\|> nctId: NCT06279728 id: DS1062-0003-EAP-MA briefTitle: Medical Access Program for Datopotamab Deruxtecan in NSCLC Patients overallStatus: AVAILABLE date: 2024-02-28 date: 2024-04-08 name: Daiichi Sankyo class: INDUSTRY name: AstraZeneca briefSummary: The purpose of this Medical Access Program (also referred to as an Expanded Access Program in the USA) is to provide access to Dato-DXd for eligible patients with previously treated advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) who, in their treating physician's opinion, have an unmet clinical need, are unlikely to obtain optimal benefit from currently approved and commercially available drugs, and who cannot enter a suitable clinical trial. conditions: Advanced Non-Small Cell Lung Cancer conditions: Metastatic Non Small Cell Lung Cancer studyType: EXPANDED_ACCESS name: Datopotamab deruxtecan sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Queen's Medical Center status: AVAILABLE city: Honolulu state: Hawaii zip: 96813 country: United States name: Principal Investigator role: CONTACT lat: 21.30694 lon: -157.85833 hasResults: False
<\|newrecord\|> nctId: NCT06279715 id: 3437 briefTitle: DFI and Aneuploidies overallStatus: ACTIVE_NOT_RECRUITING date: 2024-01-19 date: 2024-12-31 date: 2025-02-01 date: 2024-02-28 date: 2024-02-28 name: Clinique Ovo class: INDUSTRY briefSummary: IVF is the most commonly employed form of assisted reproductive technologies (ART) for the 10-15% of couples who face difficulties becoming pregnant. Many individuals elect to have their IVF-derived embryos analyzed using pregenetic implantation testing for aneuploidies (PGT-A). The use of PGT-A is particularly beneficial for patients at higher risk for aneuploidy, such as those of advanced maternal age and those faced with recurrent pregnancy loss or recurrent implantation failure.
Segmental aneuploidies are generated when a small piece of a chromosome is gained or lost during cell division, resulting in subchromosomal copy number (CN) changes. The frequency of segmental aneuploidies during the cleavage stage varies between studies, from as low as 3.9% to 15% and up to 70 % with no reported correlation with maternal age. This can be explained by the fact that, unlike whole chromosome aneuploidies, segmental aneuploidies most often involve paternally inherited chromosomes. conditions: Embryo Disorder studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 800 type: ESTIMATED name: Preimplantation Genetic Testing for Aneuploidy measure: DFI association and aneuploidy sex: ALL minimumAge: 18 Years maximumAge: 43 Years stdAges: ADULT facility: Clinique ovo city: Montreal state: Quebec zip: H4P 2S4 country: Canada lat: 45.50884 lon: -73.58781 hasResults: False
<\|newrecord\|> nctId: NCT06279702 id: OCalisir briefTitle: Serious Game Simulation and Comics in School Students overallStatus: ACTIVE_NOT_RECRUITING date: 2023-07-19 date: 2025-07-19 date: 2025-07-19 date: 2024-02-28 date: 2024-02-28 name: TC Erciyes University class: OTHER briefSummary: The aim of the study is to determine the effect of first aid training for injuries given to secondary school students through serious game simulation and comic books on knowledge, skills and motivation.
Hypotheses:
H1: First aid training given through simulation applications affects the level of knowledge.
H2: First aid training given through simulation applications affects the skill level.
H3: First aid training given with simulation application affects motivation.
H4: First aid training given with comics affects the level of knowledge.
H5: First aid training given with comic books affects the skill level.
H6: First aid training given with comics affects motivation.
METHOD: The research will be conducted as a randomized controlled experimental study with a pre-test-post-test design with children studying in the 5th and 6th grades of schools in the central district of Aksaray. One group will be given first aid training for injuries prepared with serious games, the other group will be given first aid training for injuries prepared with comic books. No intervention will be made to the control group. Serious game scenario software prepared based on the literature will be integrated into the computer. Appropriate statistics will be made after the research by applying the prepared data collection tools. With this research, the gap in the literature will be filled, children's first aid knowledge and skills in injuries will be increased, and school health nurses will be provided with up-to-date teaching material. conditions: First Aid studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: serious game and comics primaryPurpose: PREVENTION masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 54 type: ACTUAL name: SERIOUS GAME name: COMICS measure: Motivation Scale for Teaching Materials measure: Student Knowledge Level Evaluation Form for First Aid Application in Injuries measure: Student Skill Level Evaluation Form for First Aid Application in Injuries sex: ALL minimumAge: 9 Years maximumAge: 12 Years stdAges: CHILD facility: Özlem Çalışır city: Aksaray state: Center zip: 68200 country: Turkey lat: 38.37255 lon: 34.02537 hasResults: False
<\|newrecord\|> nctId: NCT06279689 id: CJTCDZ2301 briefTitle: Echography Study_Anthropometric Measurements overallStatus: NOT_YET_RECRUITING date: 2024-02 date: 2024-06 date: 2024-06 date: 2024-02-28 date: 2024-02-28 name: Crossject class: INDUSTRY briefSummary: This is a multi-center, exploratory, estimation study in both adult and pediatric populations. There is no investigational product injection during this study The exploratory objective of this study is to evaluate the anatomical characteristics of both anterolateral thighs in healthy adult and healthy pediatric populations (2 to 17 years old) by ultrasound scan before and while applying a force similar to the ZENEO® triggering force.
In the healthy adult population, anatomical characteristics of one shoulder (deltoid) and one upper arm (biceps and triceps) will also be evaluated by ultrasound scan before and while applying a force similar to ZENEO® triggering force.
Only ultrasound procedures will be performed using an investigational ultrasound system. All subjects will be asked to undergo 1 on site visit (Study Visit) during which the eligibility assessment and the ultrasound scans will be performed. conditions: Healthy Subjects studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 90 type: ESTIMATED name: Ultrasound scans measure: STBD : Skin To Bone Distance measure: STMD: Skin To Muscle Distance measure: Thickness of skin layers (dermis, hypodermis) measure: Thickness of muscle layers measure: Circumferences measurements (thigh, upper arm, waist, hip) sex: ALL minimumAge: 2 Years maximumAge: 70 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<\|newrecord\|> nctId: NCT06279676 id: SaFeGreff briefTitle: Improvement of Women's Health After Allogeneic Stem Cell Transplantation acronym: SaFeGreff overallStatus: NOT_YET_RECRUITING date: 2024-07 date: 2028-07 date: 2028-12 date: 2024-02-28 date: 2024-02-28 name: Ciusss de L'Est de l'Île de Montréal class: OTHER name: Centre hospitalier de l'Université de Montréal (CHUM) briefSummary: The aim of this prospective research project is to better understand vulvovaginal cGVHD to improve care of allografted women. The expected outcomes include better knowledge of the incidence and manifestations of vulvovaginal cGVHD, risk factors, response to treatments and impact on sexual health of allotransplanted female patients. The knowledge acquired will allow transplant clinicians to make more precise recommendations for gynecological management of future allografted women. conditions: GVHD, Chronic studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 100 type: ESTIMATED measure: Define the incidence and describe clinical presentation of vulvovaginal cGVHD after allogeneic stem cell transplants reflecting modern transplant practice. measure: Evaluate genital cGVHD treatment response measure: Evaluate the frequency of premature ovarian failure measure: Measure the incidence and prevalence of HPV infection measure: Evaluate the quality of life (QoL) of allografted women measure: Evaluate intimacy within relationships of allografted women measure: Evaluate sexual function of allografted women measure: Evaluate sexual distress of allografted women sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<\|newrecord\|> nctId: NCT06279663 id: NSTE-ACS Multivessel Trial briefTitle: Management Tactics for Patients High Risk With Acute Coronary Syndrome Without ST Segment Elevation and Multivessel Coronary Artery Disease acronym: NSTE-ACSMT overallStatus: RECRUITING date: 2024-02-29 date: 2028-12-31 date: 2029-12-31 date: 2024-02-28 date: 2024-03-13 name: Federal State Budgetary Institution National Medical Research Center named after academician E.N. Me class: OTHER_GOV name: Kemerovo Cardiology Center, Tarasov Roman Sergeevich name: Tomsk National Research Medical Center of the Russian Academy of Sciences, Ryabov Vyacheslav Valeryevich briefSummary: The study will include patients with acute coronary syndrome without ST segment elevation and multivessel CA lesion, who are subject to surgical treatment according to KG data (Syntax Score 23 - 32 points with significant damage to the anterior descending artery and/or trunk of the left coronary artery). The patient should be suitable for both CABG and PCI (confirmed by an X-ray surgeon and a cardiac surgeon). An X-ray surgeon and a cardiac surgeon, within the framework of planning the volume of revascularization, strives for the fullest feasible volume. Complete myocardial revascularization (that is, the desire for the absence of hemodynamically significant coronary arteries after revascularization, with a diameter of \> 2.5 mm, that is, residual coronary artery stenosis of no more than 60%). Thus, patients will be randomized into groups in a ratio of 1:1. Each group will need to include 230 patients (a total of 460). In the main group, revascularization will be performed by PCI, in the control group by CABG. conditions: Coronary Syndrome, Acute, Non-ST Elevation, High Risk Patients studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 460 type: ESTIMATED name: Revascularization measure: Death from any cause measure: Combined endpoint (death from cardiovascular causes, MI, Stroke, repeated unplanned myocardial revascularization) measure: target LDL level measure: Myocardial infarction measure: Stroke measure: Repeated unplanned myocardial revascularization measure: Duration of the hospital period measure: Intra/perioperative complications measure: Significant hemorrhagic complications (grade 3 or more on the BARC scale) measure: Questionnaire sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Anton status: RECRUITING city: Novosibirsk state: Novosibirsk Obl zip: 630055 country: Russian Federation name: Anton Obedinskiy, 1 role: CONTACT phone: +73833476099 phoneExt: 1 email: [email protected] lat: 55.0415 lon: 82.9346 facility: Anton status: RECRUITING city: Novosibirsk state: Rechkunovskaya Str. zip: 630055 country: Russian Federation name: Anton Obedinskiy role: CONTACT phone: 89139322885 email: [email protected] lat: 55.0415 lon: 82.9346 hasResults: False
<\|newrecord\|> nctId: NCT06279650 id: 2022-2741 briefTitle: Self-hypnosis Training for Chronic Pain Management overallStatus: RECRUITING date: 2024-02-01 date: 2024-06 date: 2024-12 date: 2024-02-28 date: 2024-02-28 name: Ciusss de L'Est de l'Île de Montréal class: OTHER briefSummary: Title: Self-hypnosis training in chronic pain management: A pilot study Our primary objective concerns the effect of hypnosis intervention on change in 24h pain between T0 (pre-intervention) and T4 (3-month follow-up). The secondary objectives concern the effects of the intervention on (i) change in 24h pain between T0 and T5 (6-month follow-up), (ii) changes from T0 in measures of the functional impact of pain, (iii) changes from T0 in anxiety-depression scores and (iv) changes from T0 in quality of life.
The study design is a Randomized efficacy pilot study. The study focuses on patients practicing self-hypnosis within HMR groups. The study population is pain clinic patients. The sample size is 60 pain clinic patients. Study duration: February 2024 - December 2024. Center responsible for the study: Centre de Recherche de l'Hôpital Maisonneuve-Rosemont (CR-HMR) - CEMTL, Montreal, Quebec, Canada.
Adverse events: none expected. conditions: Hypnosis, Chronic Pain Management studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: PARTICIPANT count: 60 type: ESTIMATED name: Self-hypnosis name: Psycho-education and cognitive Bahavioral therapy (CBT) measure: Time 1 : Numerical Rating Scale (NRS) from 0 to 10 measure: Time 1 : Questionnaire Brief Pain Inventory (BPI) measure: Time 1 : Hospital anxiety and depression scale (HADS) measure: Time 1 : SF-36 (36-Item Short Form Survey) measure: Time 1 : Questionnaire socio-demographic and clinical measure: Time 2 : Numerical Rating Scale (NRS) from 0 to 10 measure: Time 2 : Questionnaire Brief Pain Inventory (BPI) measure: Time 2 : Hospital anxiety and depression scale (HADS) measure: Time 2 : SF-36 (36-Item Short Form Survey) measure: Time 3 : Numerical Rating Scale (NRS) from 0 to 10 measure: Time 3 : Questionnaire Brief Pain Inventory (BPI) measure: Time 3 : Hospital anxiety and depression scale (HADS) measure: Time 3 : SF-36 (36-Item Short Form Survey) measure: Time 4 : Numerical Rating Scale (NRS) from 0 to 10 measure: Time 4 : Questionnaire Brief Pain Inventory (BPI) measure: Time 4 : Hospital anxiety and depression scale (HADS) measure: Time 4 : SF-36 (36-Item Short Form Survey) measure: Time 5 : Numerical Rating Scale (NRS) from 0 to 10 measure: Time 5 : Questionnaire Brief Pain Inventory (BPI) measure: Time 5 : Hospital anxiety and depression scale (HADS) measure: Time 5 : SF-36 (36-Item Short Form Survey) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: 5415 Bd de l'Assomption status: RECRUITING city: Montréal state: Quebec zip: H1T 2M4 country: Canada name: David Ogez role: CONTACT email: [email protected] lat: 45.50884 lon: -73.58781 hasResults: False
<\|newrecord\|> nctId: NCT06279637 id: PRO00046457 briefTitle: Joint Patient and Caregiver Intervention for Older African Americans With Type 2 Diabetes overallStatus: NOT_YET_RECRUITING date: 2024-03-04 date: 2026-07 date: 2026-07 date: 2024-02-28 date: 2024-02-28 name: Medical College of Wisconsin class: OTHER briefSummary: This study will test the preliminary efficacy of a joint patient/informal caregiver telephone-delivered intervention that includes diabetes education; problem solving around social needs; and behavioral activation for older African Americans with poorly controlled type 2 diabetes by randomizing 100 patient/caregiver dyads to the Joint Home intervention (n=50) and usual care (n=50) arms.
The aims of the study are:
Aim 1: To test the preliminary efficacy of home-based, joint patient and caregiver intervention (Joint Home-DM-BAT) on patient clinical outcomes (hemoglobin A1c, blood pressure, and LDL-Cholesterol).
Aim 2: To test the preliminary efficacy of home-based, joint patient and caregiver intervention (Joint Home-DM-BAT) Joint Home DM-BAT on patient quality of life.
Aim 3: To test the preliminary efficacy of home-based, joint patient and caregiver intervention (Joint Home-DM-BAT) on caregiver quality of life and caregiver burden. conditions: Type 2 Diabetes studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: HEALTH_SERVICES_RESEARCH masking: DOUBLE whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 100 type: ESTIMATED name: Joint Home-DM-BAT Intervention name: Usual Care measure: Glycemic Control (Hemoglobin A1C [HbA1C]) sex: ALL minimumAge: 50 Years maximumAge: 120 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<\|newrecord\|> nctId: NCT06279624 id: NRCT9-4 briefTitle: Effectiveness of the PCV13 in Older Thai Adults overallStatus: NOT_YET_RECRUITING date: 2024-02 date: 2025-03 date: 2025-06 date: 2024-02-28 date: 2024-02-29 name: Mahidol University class: OTHER name: National Research Council of Thailand briefSummary: This is the matched 1:2 case-control study, prospectively collect case and control who are diagnosed with pneumococcal or non-pneumococcal community acquired pneumonia (CAP), accordingly from November 2023 through October 2024. The investigators define a CASE as a person aged ≥60 years due to pneumococcal confirmed CAP either in-patients or out-patients by doctor in charge. While a CONTROL is defined as a person aged ≥60 years due to non-pneumococcal confirmed CAP either in-patients or out-patients by doctor in charge.
The goal of this observational study is to evaluate the effectiveness of the 13-valent pneumococcal conjugate vaccine (PCV13) in pneumococcal CAP in Thai adults aged ≥ 60 years with or without any medical conditions.

Subsets and Splits

No community queries yet

The top public SQL queries from the community will appear here once available.